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The ability of filarial parasites to persist in an immunological competent host, has led to the suggestion that they have evolved specific measures to counter immune defences. Filarial nematodes produce and secrete excretory-secretory (ES) products, some of which have been described to have a potential role in immune evasion.  As part of these ES products, two homologues of the mammalian cytokine macrophage-migration inhibitory factor (MIF) have been described from the filarial nematode Brugia malayi, Bm-MIF-1 and Bm-MIF-2. 

Mammalian MIF is a widely distributed protein constitutively expressed in many immune and non-immune cell types. Although firstly characterised by its ability to stop migration of peritoneal macrophages, it has now been shown to play an important role during different inflammation processes. 

The main aim of this study is to elucidate the role of Brugia MIF homologues and their relation with the mammalian cytokine. This thesis studies the effect of both filarial and host MIF homologues on two major immune cell types, macrophages and dendritic cells (DC).

We found that both Brugia and mouse-MIF synergise with IL-4 to activate macrophages to an alternative phenotype, by enhancing expression of IL-4-induced alternative activation markers Arginase-1, Ym-1 and the macrophage Mannose Receptor.  MIF also synergises with IL-4 to render macrophages suppressive, an important outcome during filarial infection. 
Additionally we found that MIF homologues induce IL-4Ra expression, suggesting a mechanism by which MIF enhances IL-4 activation. 

We showed that filarial and mouse MIF homologues differ in their capacity to activate bone marrow-derived immature dendritic cells. Mouse-MIF up-regulates MHC-II and CD40 expression and induces pro-inflammatory cytokine production after overnight treatment. On the other hand Bm-MIF-2 induces low levels of cytokine production but does not up-regulate activation markers, and Bm-MIF-1 failed to activate DC. 

Furthermore, we demonstrate that filarial MIF homologues impair DC differentiation from bone marrow precursors. While bone marrow cells cultured in the presence of GM-CSF, with or without mouse-MIF, differentiate into CD11c+ DC, addition of Bm-MIF-2 to the culture media impairs differentiation arresting the cells in an undifferentiated phenotype characterised by the expression of myeloid and granulocyte markers CD11b and GR1.  







AAMf: Alternative Activated Macrophage
ALT: Abundant Larval Transcript
AP: Alkaline Phosphatase
APC: Antigen Presenting Cell
Bm-: Brugia malayi
BM: Bone Marrow
BM-DC / BM-Mf: Bone Marrow-derived Dendritic Cell / Macrophage
BSA: Bovine Serum Albumin
CAMf: Classical Activated Macrophage
Con A: Concanavalin A
DC: Dendritic Cells
ELISA: Enzyme Linked Immuno-Sorbent Assay
ERK: Extracellular-signal Regulated Kinase
ES: Excretory-Secretory
FACS: Fluorescence Activated Cell Sorter
GAPDH: Glyceraldehyde-3-phosphate dehydrogenase
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GM-CSF: Granulocyte Monocyte-Colony Stimulating Factor
HRP: Horseradish Peroxidase
IFN-g: Interferon gamma 
Ig: immunoglobulin 
IL: Interleukin
IL-4Ra: Interleukin 4 Receptor alpha chain
iNOS: inducible Nitric Oxide Synthase
JNK: c-Jun amino-terminal kinase
LB: Luria-Bertani media
LC: Langerhan cell 
LPS: Lipopolysaccharide
MAPK: Mitogen Activated Protein Kinase
M-CSF: Monocyte-Colony Stimulating Factor
Mf: Macrophage
Mf: Microfilariae
MHC-II: Major Histocompatibility Complex class II
MIF: Macrophage-migration Inhibitory Factor
MMR: Macrophage Mannose Receptor
Mo: monocyte
MSC: Myeloid Suppressor Cell
NES: Nippostrongilus brasiliensis ES
NO: Nitric Oxide
PBMC: Peripheral Blood Mononuclear Cells
PBS: Phosphate Buffer Saline
PEC: Peritoneal Exudates Cells




TGF-b: Transforming Growth Factor beta
Th: T helper
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TNF-aTumor Necrosis Factor alpha 
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During infection parasites face the host immune system, which depends on an intricate network of soluble messengers: the cytokines and chemokines. Pathogens encompass a highly diverse set of organisms, each of which has evolved a distinctive suit of survival mechanisms. For example, viral pathogens devote a considerable portion of their compact genomes to products that frustrate cytokine activity by mimicry or inactivation of key mediators and receptors (Alcami and Koszinowski, 2000).
Parasitic helminths represent an extreme of the spectrum of pathogens, being large multicellular organisms. While individual species of parasites have evolved a wide range of infection strategies, mammalian hosts respond in a remarkably consistent manner. Typically, helminth parasites induce type 2 cytokines IL-4, IL-5, IL-10 and IL-13, as well as IgE and the expansion and mobilization of effector cells such as mast cells, eosinophils and basophils (Maizels et al., 2004).

There are different hypotheses as to why distantly related parasites generate such similar responses (Maizels et al., 2004): 
1.	It is possible that parasitic worms share molecular pattern markers that will be recognised by the innate immune system, preferentially triggering Th-2 responses in an equivalent manner to microbial recognition through TLR and initiation of Th-1 responses.
2.	Lack of stimulation of the innate immune system by helminth parasites may result in a default Th-2 response.
3.	Helminths manipulate the Th-1/Th-2 balance to take advantage of the anti-inflammatory aspects of type 2 responses.
4.	Helminths exploit loopholes in the host immune system either towards the generation of a beneficial environment, or the suppression of the host defence mechanisms.





The parasitic nematode Brugia malayi is one of the causative agents of human lymphatic filariasis, a tropical disease with over 120 million people infected worldwide (World Health Organization). 
Filarial nematodes infect the human host and migrate to the lymphatic lumen, where the adults reside and females release thousands of microfilariae each day into the peripheral circulation. Although filariasis presents a broad spectrum of clinical states, we can divide infected individuals in to two major groups: microfilaraemic (asymptomatic) individuals with no symptoms of infection, and amicrofilaraemic individuals that have developed chronic disease. Immunity in asymptomatic individuals is associated with balanced Th-1/Th-2 responses, while chronic infections are of a modified Type 2 (Maizels and Yazdanbakhsh, 2003). 
Microfilaraemic, pathology-free, individuals are characterised by high IL-4, IL-10 and IgG4, low IL-5 and IFN-g, and show down-regulation of antigen specific cellular responses. On the contrary, amicrofilaremic patients with chronic lymphoedema, have higher IgE and IFN-g and intact antigen specific responses (Lawrence, 2001).  These contrasting observations in disease states suggest that different stages of the parasite life cycle induce distinct immune responses.

1.2	Life cycle.
Infective larvae (L3) enter the human host through the skin after a mosquito bite. L3 migrate to the lymphatics where they develop into adults. Male and female adults mate in the lymphatic vessels and produce microfilariae (Mf), which migrate through the lymphatics into the peripheral circulation. The cycle is completed when mosquitoes take Mf from the blood in the next meal.  Each of the major life cycle stages (Mf, L3 and adults) has unique immunological characteristics. 











1.3	B. malayi molecular immunomodulation.
How helminths downmodulate host immune responses at the molecular level is subject of intense research in a reductionist, gene-by-gene manner. Much of this research has been focused on homologues of mammalian immune related genes, although important products also include novel parasite specific proteins such as A. viteae ES-62, which induces Th-2 responses and LPS-refractory inhibition of pro-inflammatory cytokines (Goodridge et al., 2005) (Marshall et al., 2005), S. mansoni IPSE, induces IgE and IL-4 production (Schramm et al., 2006; Schramm et al., 2007) and smCKBP, the first described chemokine binding protein from a pathogen (Smith et al., 2005).  Another examples include the B. malayi ALT genes which, in a transfection system, promote intracellular survival of Leishmania parasites and GATA-3 and SOCS-1 expression by infected macrophages (Gomez-Escobar et al., 2005); and Fasciola hepatica TPx, which by inducing alternative activation of macrophages contribute to the general immune down-regulation observed during infection (Donnelly et al., 2005).

Filarial parasites produce and secrete excretory-secretory (ES) products some of which have been described to have a potential role in immune evasion. Different stages of the life cycle express different levels of these genes (Maizels and Yazdanbakhsh, 2003).  
Potential B. malayi immune evasion genes have been characterised according to different criteria; a) major surface or secreted proteins with immunological relatedness, b) homologues of mammalian cytokines, c) novel abundantly expressed proteins (Maizels et al., 2001). 
B. malayi cystatin homologues form part of the first group. Bm-CPI-2, a bi-functional inhibitor of both conventional cysteine proteases and asparaginyl endopeptidase, is constitutively expressed by all the stages of the life parasite and has been shown to inhibit MHC-II mediated antigen processing (Manoury et al., 2001; Hartmann and Lucius, 2003; Murray et al., 2005).  Also from this group, Bm-SPN-2 is a microfilaria-specific protein that inhibits the neutrophil-specific serine proteases cathepsin G and neutrophils elastase (Zang et al., 1999). 
Two sets of cytokine homologues from B. malayi so far characterised are related to the Transforming Growth Factor-b (TGF-b) and the Macrophage-migration Inhibitory Factor (MIF), Bm-TGH-1 and -2 (Gomez-Escobar et al., 1998; Gomez-Escobar et al., 2000), and Bm-MIF-1 and 2  (Pastrana et al., 1998; Zang et al., 2002). These homologues belong to ancient gene families conserved across the metazoa, bearing 28-42% amino acid identity between filarial and human proteins. 
 Finally, by focusing on highly expressed genes within the life cycle stage associated with primary invasion (L3), novel parasite-specific proteins have been identified, the Abundant Larval Transcript (ALT) family (Gregory et al., 2000), and the Venom allergen Ancylostoma secreted protein-Like family (VAL) (Murray et al., 2001).

The present study focuses on the MIF family members from filarial parasites and their relation with mammalian homologues. 

2	Macrophage-migration Inhibitory Factor.
Mammalian MIF was first described as a soluble factor released from lymphocytes during delayed hypersensitivity reactions, with the ability to inhibit random migration of macrophages (Bloom and Bennett, 1966; David, 1966), hence its name. In the context of immune and inflammatory responses, MIF is released both systemically by the anterior pituitary gland (Bernhagen et al., 1993) and locally by cells such as macrophages (Calandra et al., 1994), T cells (Bacher et al., 1996) and eosinophils (Rossi et al., 1998). An important neuroendocrine factor, MIF is regarded as a key regulator of innate and acquired immunity.
2.1	Mammalian MIF.
2.1.1	MIF protein biochemical characteristics.
Mammalian MIF is a 115-amino acid protein of 12,000 molecular weight that forms homotrimers. Human and mouse MIF are constitutively expressed and secreted, despite containing no apparent N-terminal signal sequence in either case. 
A striking feature of MIF homologues is their enzymatic capacity. Both human and mouse MIF have tautomerase activity which is dependent on the first proline (Rosengren et al., 1996), and oxidoreductase activity dependent on the CXXC motif at positions 57-60 (Kleemann et al., 1998), although no physiological substrates have been found. 






These residues are also common to other MIF homologues in non-mammalian species.  Most importantly, all MIF homologues described to date have conserved residues 2, 34, 66, 97 and 101, which conform the catalytic site of MIF tautomerase activity  (Fig. 1.2 highlighted).
The catalytic activities of MIF and the pattern of invariant residues that conserve the catalytic site, suggest that the catalytic site is important in the biology of MIF. Mutational analysis has shown that changing proline-2 into a glycine completely abolishes tautomerase activity. There is, however, a discrepancy regarding the activity of P2G mutants, as some studies showed reduced biological activity (Swope et al., 1998; Onodera et al., 2000), but others suggest there is no correlation between tautomerase activity and the biological effect of MIF (Bendrat et al., 1997; Hermanowski-Vosatka et al., 1999).
2.1.2	MIF mediated intracellular signalling.
MIF can be released from pre-formed intracellular stores and may therefore be one of the first secreted products following cell activation (Calandra et al., 1994). Furthermore, it can act in an autocrine fashion, in both immune and endocrine cells, signalling to the MIF producing cells. 
The mechanisms of MIF signal transduction are poorly understood but it has been demonstrated that MIF stimulates both transient and sustained activation of p44/42 extracellular signal-regulated (ERK) mitogen-activated protein kinases (MAPK) both in fibroblasts and macrophages (Mitchell et al., 1999; Lue et al., 2006). 
At the intracellular level, MIF has been shown to localise with Jun activation domain-binding protein 1 (Jab-1) in the cytosol, and binding of MIF to Jab-1 inhibits Jab-1 activities. Through binding of Jab-1, MIF antagonises stimulation of activator protein-1 (AP-1) activity. MIF inhibits both c-Jun amino-terminal kinases (JNK) activation and cell cycle regulation mediated by Jab-1 (Kleemann et al., 2000). 
Finally, MIF induces phosphorylation of ELK-1, a member of the Ets family of transcription factors that mediates expression of TLR-4 (Roger et al., 2001) Figure 1.3 shows a diagram of MIF signalling pathways. 
2.1.3	MIF and CD74.













Further evidence that CD74 is involved in MIF signalling has recently been reported in 2 additional studies. In the first one MIF-CD74-CD44 complexes were immunoprecipitated in cultured carcinoma cells (Meyer-Siegler et al., 2004), and in another blocking antibodies to either MIF or CD74 attenuated growth and invasion of prostate cancer cells (Meyer-Siegler et al., 2006). 

2.2	MIF and the immune response.
MIF was initially described as a soluble factor released from T cells and hence was considered to be a mediator of acquired immunity. However, MIF is also released from macrophages after stimuli and it is now known to have an important role in innate immune responses. In this context, MIF is generally viewed as a pro-inflammatory cytokine promoting innate and adaptive immune responses through the activation of macrophages and T cells (Lue et al., 2002; Calandra et al., 2003)
2.2.1	MIF and innate immunity.
The innate immune system provides the first line of defence against pathogens and activation of innate immunity is critically dependent upon the action of cytokines. MIF, for example, is released by both macrophages and DC after stimulation with LPS, Gram-positive exotoxins, glucocorticoid or pro-inflammatory cytokines (Calandra et al., 1994; Popa et al., 2006). MIF then acts in both autocrine and paracrine fashions, activating cells to produce pro-inflammatory cytokines, and counteracting glucocorticoid activity at the site of infection. MIF directly or indirectly promotes production of a large panel of inflammatory cytokines (such as TNF-a, IFN-g, IL-1b, IL-2, IL-6, IL-8), nitric oxide, prostaglandins and several matrix metalloproteases (Calandra et al., 1995; Calandra et al., 1998). 
MIF-deficient macrophages have been found to be unresponsive to LPS and Gram-negative bacteria but not other stimuli. This was shown to be due to reduced expression of TLR-4 in MIF deficient macrophages. MIF up-regulates expression of TLR-4 and in this way facilitates the detection of endotoxin-containing bacteria and the initiation of immune responses (Roger et al., 2001). 
These observations suggest that MIF is a potent mediator of the host response to infection. However, high MIF levels can be harmful during acute infection, and antibody neutralisation of MIF in inflammatory situations has been shown to ameliorate septic-shock and autoimmune disease (Calandra et al., 2000) (Denkinger et al., 2003).
2.2.2	MIF and acquired immunity.
In addition to its function in innate responses, MIF has also been shown to play an important role in adaptive immunity. T cells up-regulate both MIF-mRNA expression, and MIF secretion after mitogenic stimulation. Furthermore, MIF contributes to T cell activation, as MIF-specific antibody depletion decreased T cell proliferation, and antigen specific IgG production (Bacher et al., 1996). However, MIF released from tumour cells has been shown to inhibit T cell activation (Yan et al., 2006).  These studies differ in the concentration of MIF that the cells are exposed to. While low doses of MIF were found to stimulate T cell activity, high doses released from tumour cells were shown to have an inhibitory effect on the same cells. This is consistent with the observations by Calandra et al, that MIF effect on macrophages follows a bell-shape curve.
2.2.3	MIF, inflammation and infection.
The relevance of MIF during different disease and infection situations has now become apparent in studies using recombinant MIF protein, MIF deficient mice and antibody depletion. MIF has been demonstrated to participate in the pathology of both acute and chronic inflammation responses including sepsis (Calandra et al., 2000), acute respiratory distress syndrome, asthma (Wang et al., 2006), arthritis (Kim et al., 2007), inflammatory bowel disease, atopic dermatitis, glomerulonephritis, allograft rejection, and artherosclerosis (Morand et al., 2006) (Lue et al., 2002).
Crucially, MIF exacerbates endotoxic shock induced by either LPS or live Escherichia coli. In vivo recombinant MIF administration increases mortality either following LPS injection or in lethal bacterial peritonitis. On the other hand, the use of specific blocking MIF antibodies increases survival in these situations (Bernhagen et al., 1993; Calandra et al., 2000). Furthermore, MIF is implicated in responses to Gram-positive toxins, as antibody treatment prevents death after Staphylococcal toxic shock (Calandra et al., 1998). In other settings however, MIF has been shown to be protective during bacterial infection with Pseudomonas aeruginosa, Salmonella enterica, or Listeria monocytogenes (Pollak et al., 2005), and recombinant MIF inhibits Mycobacterium tuberculosis growth in monocytes (Oddo et al., 2005).
Septic shock is characterised by disregulation of the inflammatory response, with a hyper-inflammatory phase followed by a hypo-inflammatory state. During hyper-inflammation, high levels of MIF are detrimental and anti-MIF treatment improves survival. On the other hand, in the hypo-inflammatory phase, recombinant MIF restores cytokine production and protects immunocompromised mice from bacterial superinfection (Pollak et al., 2005).

The ability of MIF to accentuate chronic inflammation is evidenced by a number of studies on several inflammatory conditions. The best evidence is from rheumatoid arthritis, in which high expression of MIF has been detected in the synovial tissue of RA patients. Furthermore, in a murine model of RA, antibody treatment markedly suppressed inflammation (Mikulowska et al., 1997).  A further example comes from studies of airway inflammation. MIF deficient mice showed lower cell recruitment, particularly reduced eosinophilia, low IgE and reduced cytokine production in the bronchoalveolar fluid (Wang et al., 2006).

Finally, and with particular relevance to this study, MIF has been shown to be important in parasitic infection. MIF-deficient mice are more susceptible to both Leishmania and Trypanosoma spp (Satoskar et al., 2001; Reyes et al., 2006); furthermore, rMIF treatment of macrophages increases Leishmania killing, suggesting that MIF is protective during intracellular parasite infection (Jüttner et al., 1998).  MIF also plays an important role during helminth infection. MIF–/– mice are more susceptible to T. crassiceps (Rodríguez-Sosa et al., 2003), and antibody treatment increased parasite burdens in a Schistosome infection model (Stavitsky et al., 2003).  In contrast to these studies, MIF release has been shown to be important in the pathogenesis of malarial anaemia (Martiney et al., 2000) and MIF-deficient mice suffer less severe malaria, and survival is increased following Plasmodium chabaudi infection (McDevitt et al., 2006). 
2.3	Brugia malayi MIF homologues.
2.3.1	Bm-MIF proteins.
Two MIF homologues have been found in B. malayi, Bm-MIF-1 and -2. With 115 amino acids, Bm-MIF-1 is identical to human and mouse MIF in size, and has 40-42% identity with the mammalian proteins (Fig. 1.2) (Pastrana et al., 1998). On the other hand, Bm-MIF-2 is 120 amino acids long, and it has 27 % identity with human-MIF and 26 % identity with Bm-MIF-1 (Zang et al., 2002). As mammalian MIF, B. malayi MIF homologues form homotrimers, and Bm-MIF-2 secondary 3D structure is superimposable with human MIF, even with only 27% identity (Fig. 1.4). Both filarial homologues contain the conserved tautomerase site, and indeed have enzymatic activity that is abolished when the first proline is mutated to a glycine (P2G), as in the Bm-MIF-1G and Bm-MIF-2G mutants. On the contrary, only Bm-MIF-1 conserves the CXXC motif in position 57-60 that is necessary for the oxidorreductase activity (Fig. 1.2). Both filarial MIF are expressed by all stages of the parasite life cycle, although expression is higher in the Mf and adult stages. 
2.3.2	Bm-MIF biological effect.
Previous studies have shown that both Bm-MIF-1 and -2 have chemoattractant effects on human monocytes, and that incubation of monocytes with either protein induces inflammatory cytokine production of TNF-a, IL-8 and endogenous MIF (Zang et al., 2002). Relevant to the context of Brugia infection, Bm-MIF-1 can partially replicate an important effect of live parasites in vivo when injected in the peritoneal cavity of mice. Bm-MIF-1 administration induces a cell infiltrate rich in macrophages and eosinophils, similar to that recruited by the adult worms in an implant model (see below). More importantly, Bm-MIF-1 up-regulated expression of a hallmark gene of macrophage alternative activation, Ym-1 (Falcone et al., 2001). We have recently observed that Bm-MIF-2, like Bm-MIF-1, also induces macrophage and eosinophil recruitment in vivo, and up-regulates alternative activation markers (Gregory et al. unpublished observations).

2.4	MIF homologues in other parasite species. 
Although Bm-MIF-1 was the first parasitic MIF homologue characterised (Pastrana et al., 1998) a number of other non-mammalian organisms are now known to express MIF-like proteins. 
2.4.1	MIF homologues in protozoa.
Although during genome sequencing projects MIF-like proteins were found both in Plasmodium (Martiney et al., 2000) and Leishmania spp., at protein level the first report of protozoan MIF homologues was the characterisation of MIF from Eimeria species, although no report on Eimeria-MIF functional activity has been made (Miska et al., 2007). 
Recently, MIF homologues from Plasmodium spp. have been reported (Augustijn et al., 2007; Cordery et al., 2007). Pf-MIF has 29% identity, and 39% similarity with human MIF, and as for Bm-MIF homologues the predicted secondary structure is highly conserved (Augustijn et. al., unpublished). Cordery’s study showed that recombinant Pf-MIF inhibits random migration of human monocytes. In this study, no significant levels of inflammatory cytokine production were detected after treatment of monocytes with Pf-MIF. In a second study, Augustijn et al. constructed MIF deficient parasites to show that Pb-MIF expression regulated host reticulocyte numbers. Thus, MIF deficiency in P. berghei resulted in higher reticulocyte density in infected mice, suggesting that parasite MIF might work in concert with the mammalian cytokine to suppress erythropoiesis in the context of Plasmodium infection. 
Although there is no protein data yet, genome sequences have revealed MIF homologues in Leishmania and Toxoplasma spp, but not in the related apicomplexan Theileria or Cryptosporidium. 
2.4.2	MIF homologues in other nematodes.
An increasing number of other nematodes have been shown to express MIF proteins including; Trichinella spiralis (Wu et al., 2003), Tricuris muris, B. pahangi (Pennock et al., 1998), Wuchereria bancrofti, and the free-living Caenorhabditis elegans (Marson et al., 2001). With more genomic and proteomic data coming available now, it is expected to find MIF homologues in other parasitic species.
Although no functional data has been reported yet, all MIF homologues characterised to date conserve the residues involved in tautomerase activity (Fig.1.2).  As for Bm-MIF-1 and -2, T. spiralis MIF homologue was found to inhibit migration of human monocytes in an in vitro assay (Tan et al., 2001). 
Finally, the free-living nematode C. elegans expresses four distinct mif genes (Ce-MIF-1-4). Ce-MIFs accumulate in somatic cells, and Ce-MIF-2 and -3 are up-regulated in the dauer stage, suggesting a role for MIF in cellular maintenance during periods that lead to developmental arrest (Marson et al., 2001). 

3	Antigen presenting cells and infection.
Host defences rely on both antigen non-specific innate responses and antigen-specific adaptive immunity. The innate immune system rapidly recognises pathogens and tissue damage and has the ability to signal the presence of danger to the adaptive immune system. 
The detection of pathogens is first carried out by sentinel cells of the immune system, the macrophages (Mf) and dendritic cells (DC) located in tissues that are in contact with the host’s natural environment, and then by circulating granulocytes and monocytes that are rapidly recruited to the site of infection. Innate cells use a variety of pathogen recognition receptors to recognise patterns shared between pathogens (Iwasaki and Medzhitov, 2004). 
Both Mf and DC precursors develop in the bone marrow, and migrate to tissues as immature progenitors where they are subject to stimulatory and suppressor signals that profoundly alter their morphology, metabolism and physiology. There is ample functional APC heterogeneity due to differences in the degree of maturation of macrophages and dendritic cells (Gordon and Taylor, 2005; Hume, 2006).
3.1	APC polarization.
Adaptive immune responses are regulated by antigen-specific T helper responses. Intracellular bacteria or viruses induce Th-1 cells, while helminth infections preferentially induce Th-2 (Sher et al., 2003). T cells are activated by APCs through 3 signals:
1)	Recognition of Ag-MHC-II complexes.
2)	Co-stimulatory signals such as B7-CD28. 
3)	Polarizing signals mediated by APC (Kalinski et al., 1999).  
The notion that APC can induce differential T cell polarization toward Th-1 and Th-2 has lead to the idea that APC themselves must be polarized towards a particular Th outcome (Fig. 1.5) (Gratchev et al., 2001). 
Among polarized APC, effector Mf are classically activated by exogenous type 1 mediators such as IFN-g, TNF-a or LPS (Mf1), while Mf2 are alternatively activated by IL-4, IL-13 or IL-10. Dendritic cells on the other hand, undergo autonomous maturation following antigen uptake, up-regulate surface MHC-II and co-stimulatory molecules, and induce Th-1 responses through the production of IL-12. These are considered mature myeloid DC or DC1. DC2, that induce Th-2 responses, are less well characterised. They maintain an immature myeloid-like phenotype and have reduced cytokine production (Banchereau and Steinman, 1998).






Heterogeneity is evidenced by the wide variety of cytokines that play a role in either DC generation or maturation. For example in vitro, GM-CSF drives inflammatory DC differentiation from myeloid precursors (Inaba et al., 1993), while Flt-3L induces plasmacytoid DC development from bone marrow (Brasel et al., 2000).
One division can be made into migratory, lymphoid-resident, plasmacytoid and inflammatory monocyte-derived type DC (Shortman and Naik, 2007).  Migratory DC function as sentinels sampling antigen in peripheral tissues, then migrating to the lymph nodes in response to danger signals; Langerhans cells (LC) in the epidermis are the model migratory DC. In contrast, lymphoid-resident DC collect and present antigens in the lymphoid organ itself, this type includes most DCs in thymus and spleen (Vremec et al., 2000).  Plasmacytoid DC (pDC), or natural interferon-producing cells, are round, non-dendritic, long-lived cells which produce large amounts of type I interferon following microbial stimuli (Liu, 2005). This same inflammatory stimuli initiates conversion of pDC into a dendritic form and the cells acquire DC antigen-processing and presentation properties (O'Keeffe et al., 2002).  Finally, inflammatory monocyte-derived DC appear as a consequence of infection or inflammation stimulation through Toll-Like Receptors induces circulating monocytes differentiation and maturation (Geissmann et al., 2003).

3.2	Alternatively activated macrophages.
The term alternative activation for macrophages was first coined by Siamon Gordon to describe the phenotype of macrophages following stimulation with the type-2 cytokine IL-4 (Stein et al., 1992) as opposed to the macrophage phenotype following INF-g stimuli. 
Type 1 stimuli such as IFN-g, TNF-a and bacterial LPS, activate macrophages in a classical way. Classically activated macrophages (CAMf are potent effector cells, which produce pro-inflammatory cytokines (TNF-a, IL-1 and IL-6) and nitric oxide (NO) and have enhanced microbicidal and tumoricidal activity (Hamilton, 2002). 
On the contrary, type 2 stimuli IL-4 and IL-13 activate macrophages through IL-4Ra inducing alternatively activated macrophages (AAMf). Following IL-4 or IL-13 stimulation Mf up-regulate the expression of macrophage mannose receptor (MMR) and members of the scavenger receptor family and up-regulate production of anti-inflammatory mediators such as TGF-b and IL-10 (Goerdt and Orfanos, 1999; Nair et al., 2006). Furthermore, AAMf down-regulate NO production as a result of their up-regulation of Arginase-1.
3.2.1	L-arginine metabolism, classical vs. alternative activation.









In addition to Arginase-1, IL-4 induces expression of characteristic genes that have become hallmarks of macrophage alternative activation; significantly these are genes which are not induced but rather are down-regulated by IFN-g
MMR: macrophage mannose receptor, is a phagocytic receptor that mediates binding and phagocytosis of microorganisms with surface mannose residues and soluble mannose-containing glycoproteins. It is expressed by peritoneal resident and elicited macrophages and by alveolar macrophages but not by monocytes (Stein et al., 1992).  
Ym-1: a member of the chitinase family, which was originally described as an eosinophil chemotactic factor produced by CD8 lymphocytes (Owhashi et al., 1998). However the higher level of Ym-1 in macrophages, and the ability to bind chitin and related glycan structures, suggest that eosinophil chemotaxis is not its primary function (Chang et al., 2001). Ym-1 has no apparent chitinase activity and its effector mechanism remains unclear.
Fizz-1: a cysteine-rich protein first found in the bronchoalveolar fluid of mice with OVA-induced pulmonary inflammation and named FIZZ1 for Found in inflammatory zone (Holcomb et al., 2000). Fizz-1 is identical to RELM-a a member of a family of tissue-specific genes with high similarity to resistin, termed resistin-like molecules (RELM). Resistin was first described as a protein produced by adipocytes that can antagonise insulin action (Steppan et al., 2001). Fizz-1/RELM-a is also produced by activated macrophages and its up-regulation is dependent on IL-4 (Loke et al., 2002).
3.2.3	AAMf functions.
AAMf up-regulate Arginase-1 and anti-inflammatory cytokines, and are hence considered to play an important role in maintaining the balance between pro- and anti-inflammatory reactions during type 1 cytokine driven inflammatory responses. In addition, it has been shown that AAMf exhibit high phagocytotic capacity and can promote angiogenesis leading to suggestions that AAMf can participate in the 3 phases of healing, 1/ down-regulation of inflammation, 2/ angiogenesis and 3/ elimination of debris (Gordon, 2003).
However, the exact function of AAMf in vivo remains unclear. Because they have been associated with type 2 cytokine controlled inflammatory diseases, it is possible that AAMf are pro-inflammatory and may contribute to the development of pathology (Hesse et al., 2001). 

3.3	Dendritic cell mediated Type 2 responses. 
Following antigen uptake, DC migrate to the lymphatic tissues where they encounter T cells and initiate T cell activation (Pulendran et al., 1999) (Macagno et al., 2007). Activation of DC following TLR stimulation by either bacterial or protozoal antigens, is also a critical event (Iwasaki and Medzhitov, 2004). TLR signalling induces surface MHC-II and co-stimulatory marker up-regulation on DC, and initiates cytokine production (IL-6, IL-10 and IL-12) (Manickasingham et al., 2003). These ‘mature’ DC mediate T cell activation, which will differentiate into Th-1-IFN-g producing cells induced by IL-12.  On the other hand, how DC mediate Th-2 activation is not clear and controversy remains as to whether DC actively mediate type 2 differentiation, or whether Th-2 develops by default in the absence of type 1 responses (Sher et al., 2003). 
Several studies using helminth-derived products have shown that DC primed with parasite antigen induce Th-2 responses in vivo. However, various helminth-matured DC do not present a common phenotype.  Nippostrongylus brasiliensis ES (NES) induces up-regulation of CD86 and CD40, but not MHC-II or CD80, and the secretion of IL-6 and IL-12p40 but not IL-12p70 or IL-10 (Balic et al., 2004). On the other hand, Schistosome egg antigen (SEA)-treated DC failed to up-regulate surface markers or cytokine production (MacDonald et al., 2002). However, both NES and SEA induced type 2 antigen-specific responses when transferred to mice in vivo. Furthermore, ES-62 a phosphorylcholine-containing glycoprotein from the filarial nematode Acanthocheilonema viteae, also induces Th-2 differentiation despite ES-62-primed DC failing to show an activated phenotype (Whelan et al., 2000). These studies favour the hypothesis that during helminth infections, DC mediate type 2 differentiation in a specific manner, rather than Th-2 developing as a result of failing to mount type 1 responses.
3.4	Brugia malayi and APC.
Previous work has shown that B. malayi parasites exert a profound effect on APC both in vivo and in vitro (Semnani and Nutman, 2004). Although B. malayi will not fully develop in laboratory mice, individual parasite stages survive for several weeks following implantation in the peritoneal cavity of adult or L3 B. malayi (Lawrence et al., 1994). Such infections induce a population of cells that suppress T cell proliferation while eliciting Th-2 cytokine production (Allen et al., 1996; Loke et al., 2000a). These effects are highly dependent on endogenous IL-4 and can be replicated using ES products in vivo (Allen and MacDonald, 1998; MacDonald et al., 1998). Characterisation of the peritoneal exudate cells (PEC) after B. malayi implantation reveals a population rich in macrophages and eosinophils (MacDonald et al., 1999).  Moreover, adherent macrophages from implanted mice inhibit proliferation via a cell-to-cell contact mechanism in an IL-4 dependent manner (Loke et al., 2000b). These B. malayi elicited macrophages exhibit a particular phenotype characterised by its morphology, suppression capacity and the expression of alternative activation markers; Arginase-1, Ym-1 and Fizz-1 (Loke et al., 2002; Nair et al., 2003). Furthermore, in the filarial rodent nematode Litomosoides sigmodontis, infection elicits alternative activated macrophages which suppress T cell proliferation at the site of infection (Taylor et al., 2006).
These observations are supported by data from human infection, as in microfilaraemic patients lymphoproliferative hyporesponsiveness is associated with diminished monocyte function (Sasisekhar et al., 2005). 
In parallel to these effects on macrophages, parasite-primed DC develop the capacity to down-regulate immune responses.  Exposure to either filarial antigen or live parasites during differentiation of DC from monocytes, impairs the responses of DC to subsequent activation by bacterial stimuli (Semnani et al., 2001; Semnani et al., 2004). Furthermore, pre-exposure to B. malayi microfilariae alters the response of immature DC to Mycobacterium tuberculosis infection as seen by reduced cytokine production and surface markers up-regulation (Talaat et al., 2006). Finally, microfilariae have been shown to reduce DC capacity to induce IFN-g and IL-5 production by CD4+ T cells (Semnani et al., 2003).

These data from in vivo and in vitro studies show the complex interactions that occur between host APC and filarial parasites, however there are still several unanswered questions. Of particular relevance for my thesis is the following question; to what extent can these effects of whole parasites and parasite products, be attributed to defined parasite molecules, in particular the MIF homologues?

4	Thesis Aims.
The association of MIF with inflammation opens the question: 
	Why would parasites, in an attempt to avoid the host immune responses, secrete molecules thought to amplify inflammation?
Thus, I sought to investigate whether MIF homologues from parasites are pro- or counter-inflammatory in their biological function and whether this is concentration dependent.  I suggest that parasite MIFs do contribute to immune evasion because either or both of the following hypotheses hold true:
	Parasite MIF contains key structural differences from mammalian cytokines which result in their exerting a counter-inflammatory influence.
	Repeated chronic exposure to parasite MIF builds a counter-inflammatory environment that is beneficial for the parasite.
Testing these hypotheses will establish whether parasite MIF are key players in immune evasion and how they may differ functionally from host MIF.
In addressing the role of MIF homologues during immune responses I studied in particular the interaction of both parasite and host MIF proteins with host antigen presenting cells.  I thus set a series of in vitro and in vivo experiments to elucidate the effect of MIF proteins on host dendritic cells and macrophages, as well as to analyse the role of host MIF during Brugia infection. Hence, I have divided my work in four main subjects:
1.	The role of MIF homologues on macrophage activation.
2.	The role of MIF homologues on DC activation.
3.	MIF effect during APC differentiation.













1.1	C57BL/6, BALB/c and 129 wild type mice were bred and maintained at the animal facilities in the University of Edinburgh. MIF deficient (MIF-/-) mice of a mixed background were a kind gift of Dr. A. Satoskar (Satoskar et al., 2001), and were subsequently bred and maintained in house.  Six to 8 week old mice were used for experimental procedures.
1.2	Brugia malayi parasites. 
Adult parasites were obtained from infected jirds (Meriones unguiculatus) purchased from TRS Laboratories (Athens, GA) or maintained in house by Y. Harcus. Adult worms and microfilariae were harvested from the peritoneal cavity of infected gerbils and washed in warm media (RPMI, Invitrogen). Adults were separated in groups of 4 females and one male. 
1.3	B. malayi peritoneal implant.	
Mice were surgically implanted intra-peritoneally (i.p.) with groups of 5 adult worms. Control mice received 0.5 ml of 4% thioglycollate medium brewer modified (Becton Dickinson) i.p. 3 days before the end of the experiment.  On day 24 after implantation mice were euthanised by brachial artery puncture under anaesthesia, peritoneal exudate cells (PEC) were harvested by lavage with 10 ml of ice-cold RPMI and spleens collected in RPMI. 
1.4	B. malayi antigen preparation.
Adult B. malayi antigen was prepared by homogenisation of mixed sex worms in PBS on ice followed by centrifugation at 10,000 x g for 20 minutes. The resultant supernatant was passed through a 0.2 m filter prior to storage at –80ºC. 




RPMI or DMEM supplemented with 10 % FCS, 2mM L-glutamine and 0.25U/ml penicillin and 100 µg/ml streptomycin (complete media) were used as culture media. All reagents were from Invitrogen.
2.2	Cell lines.
All cell lines were maintained at 37ºC in an atmosphere of 5 % CO2.
2.2.1	 The fibroblast line L929 (ATCC) was maintained in complete DMEM. Cells were grown in 175 cm2 tissue culture flasks to confluence; typically 3 days of culture. Supernatant was harvested, spun down and frozen. L929 supernatant was used as a source of M-CSF for bone marrow macrophage differentiation.
2.2.2	The X63 cell line was grown in complete RPMI. Cells were grown in roller bottles in 500 ml of media for 1 week. Supernatants were harvested and frozen. X63 supernatant was used as a source of GM-CSF for bone marrow dendritic cell differentiation. 
2.2.3	The murine lymphoma cell line EL-4 (ATCC) was routinely maintained in complete RPMI.  
2.2.4	The murine myeloma cell line SP2 was maintained in complete DMEM.  
2.2.5	The PT67 and GP+E.86 retrovirus packaging lines were maintained in complete DMEM supplemented with 10 mM HEPES and 10 µM 2-mercaptoethanol.
2.3	Bone marrow derived cells.  
Bone marrow was obtained by flushing the femurs and tibias of mice with complete media. Single cell suspensions were prepared by passing the cells through a cell strainer (Falcon, #352350). Cells were spun for 10 min at  311 g at room temperature and counted using a haemocytometer. 
2.3.1	Macrophage differentiation. BM precursors were cultured in bacterial Petri dishes in complete DMEM supplemented with 10 % FCS (20 % final concentration) and 20 % L929 supernatant (as a source of M-CSF) at 6x105 cell/ml density. On day 6 cells were washed once with warm (37ºC) PBS to remove non-adherent cells, and adherent macrophages were detached with warm 3 mM EDTA / 10 mM Glucose in PBS. Macrophages were then replated in 24- or 96-well plates at the appropriate concentration in complete DMEM without M-CSF and allowed to adhere overnight prior to treatment. Cell preparations were typically >85% F4/80 positive. 
2.3.2	Dendritic cell differentiation. BM precursors were cultured in bacterial Petri dishes in complete RPMI supplemented with 20 % X63 supernatant (as a source of GM-CSF (Stockinger et al., 1996)) at a 3.75x105 cell/ml density. Cells were fed on days 3 and 6 with fresh media. Day 7 cells were replated in 24- or 96-well plates at the appropriate concentration for treatment. Cell preparations were typically 80-90% CD11c positive. For some experiments 20 ng/ml of rmGM-CSF (Peprotech) was used instead of X63 supernatant. 
For differentiation studies (chapter 5), BM-cells were cultured with GM-CSF in the presence or absence of recombinant MIF, previously treated with polymixin-B sulphate (Sigma). 24-well plates were used, and 7.5x105 cells/well were cultured in 2 ml of media (3.75x105 cells/ml).
2.4	Purification of peritoneal macrophages by adherence.        
Peritoneal cells were harvested from control mice (resident macrophages) or mice that had received 500 µl i.p. of 4% thioglycollate 3-4 days previously (Thio-macs).  PECs were plated onto Petri dishes and allowed to adhere for 3 hours at 37ºC. Adherent cells were then harvested as described above and replated at the appropriate concentration. Cell preparations were typically >90% F4/80 positive. 
2.5	Purification of splenic macrophages.                                         
Whole spleens were collected from naïve C57BL/6 mice, and splenocyte suspensions prepared by mashing spleens through a cell strainer. Macrophages were purified by magnetic sorting using MiniMACS columns (Miltenyi) following the manufacturer’s protocol. CD11c-beads (Miltenyi) were used for negative selection, followed by CD11b-biotin (BD) and extravidin-beads (Miltenyi) for positive selection of macrophages. Macrophage purity was confirmed by F4/80 staining. 
2.6	Purification of human PBMC.
PBMC were purified by CD14 positive selection of Buffy coats.  Cells were incubated with 80 ng/ml huGM-CSF and 500 U/ml huIL-4 (Biosource) in 75 cm2 flasks for 6 days. Media wash replaced every 3 days, and on day 6 cells were replated at the appropriate concentration for treatment. 




PEC were harvested by peritoneal lavage with ice-cold RPMI containing antibiotics. Cells were washed in RPMI and 2x105 cells were cytospun for 5 min at 500 rpm onto glass slides using a Shandon Cytospin. Slides were allowed to dry overnight and stained with Diff Quick (Dade) following the manufacturer’s instructions. Cell populations were determined by microscopy examination (x100 objective) of 300 cells per slide. 
3.2	FACS staining.
Cells were immunostained for analysis by flow cytometry. Cells were incubated with rat IgG to block Fc receptors. After washing twice in FACS buffer (0.1 % BSA-PBS) cells were incubated with the appropriate antibodies at 4ºC for 20 minutes. Where a second step was needed, cells were incubated at 4ºC for 20 minutes with streptavidin-PerCP.  For intracellular staining cells were fixed for 20 minutes at 4ºC using BD Cytofix/Cytoperm. Cells were then incubated with the desired antibodies in Perm/Wash buffer (BD). After the final staining step cells were washed twice and resuspended in 300 µl of FACS buffer for acquisition. Cells were analysed using a FACScaliber (BD) and FlowJo software.  Table 2.1 shows a list of the antibodies used for FACS. 
3.3	Spleen cell re-call and proliferation assay.
To obtain single cell suspensions, spleens were mashed through a cell strainer and red blood cells were lysed using an isotonic buffer (Sigma, Red Blood Lysing Buffer). Splenocytes were plated in 96-well plates at 1x106 cells/well. Cells were stimulated with medium alone, specific antigen (10 g/ml) or Concanavalin A (Con A) (1 g/ml). Following stimulation for 72 hours, 150 l supernatants were removed for cytokine assays and 1Ci of [3H]TdR in 10 l complete medium was then added to each well. Plates were incubated overnight before harvesting and counting using a liquid scintillation counter (Microbeta 1450, Trilux). Results were plotted in counts per minute (cpm).

Table 2.1. List of antibodies used for FACS staining.
Antibody	Clone	Conjugate	Isotype	Comments
CD11c	N148	APC	Hamster IgG1	DC Phenotype
CD11b  (Mac-1)	M1/70	Biotin	Rat IgG2b	APC Phenotype
F480	BM8	Alexa-488 or PE	Rat IgG2a	Mac Phenotype
SiglecF	E50-2440	PE	Rat IgG2a	Eosinophils Phenotype
Gr-1(Ly6G-Ly6C)	RB6-85C	FITC	Rat IgG2a	Granulocyte Phenotype
MHCII	2G9M5/114.15.2	FITCPE	Rat IgG2a	APC Activation state
CD80(B7-1)	16-10A1	PE	Armenian Hamster IgG2k	APC Activation state
CD86(B7-1)	GL1	PE	Rat IgG2ak	APC Activation state
CD40	3/23	PE	Rat IgG2a	APC Activation state
IL-4Ra(CD124)	mIL4R-M1	Biotin	Rat IgG2ak	Mac Activation state




CD74 (Ii)	In-1	FITC	Rat IgG2b	Invariant chain.
7/4	7/4	Alexa 647	Rat IgG2a	Neutrophil marker.
CD115	604B5 2E11	PE	Rat IgG1	CFS-1R (c-fms)
3.4	Cytokine ELISA.
Cytokine concentrations were measured by standard sandwich ELISA. Plates were coated overnight at 4C with 50 l of the appropriate capture antibody in carbonate buffer (0.06M, pH 9.6).  Plates were then blocked with 5% BSA in TBS-0.05% Tween-20 for 2 hours at 37C. The blocking buffer was then flicked off and the plates were incubated overnight at 4C with 50 l of the sample, or doubling dilutions of the appropriate recombinant cytokine as standard.  Plates were then washed 5 times in TBS-Tween and incubated with the appropriate biotinylated antibody diluted in TBS-Tween / 1% BSA, for 1 hour at 37C.  Following washing in TBS-Tween (as before), the plates were incubated for 45 minutes at 37C with extravidin-alkaline phosphatase or extravidin-horseradish peroxidase (AP or HRP; Sigma).  Plates were then washed with TBS-Tween followed by two washes in distilled water to remove detergent. Finally, p-nitrophenyl phosphate substrate (Sigma) or ABTS peroxidase substrate (KPL) was added at 100 l/well.  Plates were read at 405 nm and cytokine concentrations of the samples were measured from the standard curve.  Table 2.2 shows a table of all antibodies used for cytokine detection by ELISA. 
3.5	Antibody ELISA.





Table 2.2. List of antibodies used for cytokine ELISA.
CaptureAntibody (concentration)	Clone and supplier	Top standard concentration	Biotinylated detection antibody (concentration)	Clone and supplier
IL-4 (2 µg/ml)	11B11, in house	8 ng/ml	5 µg/ml	BVD6-24G2, Pharmigen
IL-5 (1µg/ml)	TRFK5, Pharmingen	25 ng/ml	2 µg/ml	TRFK4, Pharmingen
IL-6 (2 µg/ml)	MP5-20F3, Pharmingen	100 ng/ml	0.5 µg/ml	MP5-32C11, Pharmingen
IL-10 (4 µg/ml)	JES5-2A5, Pharmingen	10 ng/ml	2 µg/ml	SXC-1, Pharmingen
IL-12p40 (2 µg/ml)	C15.6, Pharmingen	200 ng/ml	0.5 µg/ml	C17.8, Pharmingen
IL-12p70 (2 µg/ml)	9A5, Pharmingen	10 ng/ml	0.5 µg/ml	C17.8, Pharmingen
IL-13 (2 µg/ml)	38213, R&D	16 ng/ml	0.1 µg/ml	Rabbit polyclonal, PeproTech
IFN-g (2 µg/ml)	R46A2, in house	100 ng/ml	0.5 µg/ml	XGM1.2, Pharmingen





05) was used at 1/6000, HRP conjugated goat anti-mouse IgG2a (Southern Biotech 1080-05) at 1/200, HRP conjugated goat anti-mouse IgG2b (Southern Biotech 1090-05) used at 1/4000 and HRP conjugated goat anti-mouse IgG3 (Southern Biotech 1100-05) was used at1/1000, followed by ABTS peroxidase substrate (KPL).  Antibody titre was calculated as the lowest dilution higher than the negative control  + 3 SD. 
3.6	Western blot.
3.6.1	SDS-PAGE and transfer. Samples were mixed with 4x SDS sample buffer (Invitrogen) containing 0.4M 2-mercaptoethanol. Samples were heat-denatured at 95ºC for 5-10 min and resolved using pre-cast 10 % gradient Bis-Tris-NUPAGE gels (Invitrogen). Gels were transferred onto nitrocellulose membrane (Bio-Rad) using a semi-dry transfer system for 1 h at 0.8 mA cm–2. Membranes were blocked with 5 % milk in TBS-0.1%TritonX100-0.05% Tween 20 for 2 h at room temperature or overnight at 4ºC, followed by incubation with the appropriate antibodies. 
3.6.2	B. malayi MIF westerns. Anti-recombinant-MIF polyclonal sera were used at 1:200 dilution in 5% milk TBSTT followed by total anti-mouse IgG-HPR (DAKO) at 1:2000 dilution. ECL substrate (Amersham) was used for detection.  Membranes were exposed to photographic film (Amersham) and films scanned. 
3.6.3	MAPK phosphorylation. Following treatment, macrophages were harvested in lysis buffer, 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na3VO4, 1 µg/ml leupeptin (Cell Signaling) containing 1mM PMSF. Protein concentration was measured using BCA Protein Assay (Pierce). 10-20µg of protein were separated and transferred as described above. Membranes were blocked with milk and incubated overnight with the appropriate antibody dilution in 5% BSA. Detection was followed using anti-rabbit IgG-HRP (Cell Signaling) and ECL substrate as before.  Antibodies used were as follow: anti-phospho-p44/42 (ERK1/2), anti-phospho-p38, anti-phospho-JNK (Cell Signaling). Antibodies to the non-phosphorylated protein were used as control. 
3.7	MIF antibody depletion.
MIF recombinant proteins were incubated with 10 X excess (mg basis) of a monoclonal antibody that recognizes both Brugia and mouse homologues (2F11C9) for 2 h 30 min at 4ºC. Immunocomplexes were precipitated using 50µl of Protein G agarose/sepharose beads (Up-state). Beads were centrifuged, and supernatants were subjected to a second round of immunoprecipitation to ensure complete protein removal. 
3.8	Arginase assay.
5x105 PEC per well were plated in 96-well plates in triplicates and incubated at 37ºC overnight.  For some experiments BM-Mf or thioglycollate-elicited macrophages were treated overnight with recombinant MIF protein in the presence or absence of IL-4.  Following overnight culture cells were lysed with100 µl of 0.1% Triton X-100. After 30 min on a shaker, 100 µl of 25 mM Tris-HCl pH 7.2 and 20 µl of MnCl2 were added and arginase was activated by heating for 10 min at 56ºC. Arginine hydrolysis was conducted by incubating the lysates with 100 µl of 0.5 M L-arginine pH 9.7 at 37ºC for 60 to 120 min. The reaction was then stopped with 800 µl of H2SO4 (96%) /H3PO4 (85%) /H2O (1/3/7, v/v/v). 40 µl of 9% a-Isonitrosopropiophenone (dissolved in 100% ethanol) was then added and samples were incubated at 95ºC for 30 min. Urea concentration was then measured at 540 nm. A standard curve was prepared with known concentration of urea subjected to the same procedure, made up of 8 2-fold dilution starting at 20 mM.
3.9	Nitric oxide assay. 
NO production was assessed by measuring the accumulation of nitrite by the Griess reaction in which 100 l of Griess reagent (1% Sulphanilamide/ 0.1% N(-1-Naphthyl)-Ethylenediamino/ 5.8% Phosphoric acid) were added to 100 l of each supernatant in triplicate wells in a 96-well plate. Plates were read immediately at 490 nm against wavelength reference 620 nm using an ELISA plate reader. NaNO2 was used to make a standard curve for each plate (8 by 2-fold dilutions, starting concentration 100 M). 
3.10	Suppression assay. 
5x104 PEC per plate were plated in 96-well flat bottom plates in triplicate and incubated at 37ºC to allow adherence. After 3 hours non-adhered cells were washed off and 1x104 EL-4 cells per well were added. Co-cultures were incubated for 3 days at 37ºC and 1µCiof [3H]TdR in 10µl complete medium was then added to each well to measure proliferation as above. Results are shown as counts per minute, or as compared to EL-4 co-cultured with thioglycollate-elicited macrophages, or untreated BM-Mf.  For some experiments BM-Mf were treated overnight with recombinant MIF protein in the presence or absence of IL-4. EL-4 cells were then added and the protocol described above was followed.
3.11	Antibody production. 
3.11.1	Generation of polyclonal serum.  Five BALB/c 6-8 week old female mice were immunised with recombinant protein (Bm-MIF-1, Bm-MIF-2 or mouse-MIF). Proteins were alum precipitated for immunisation. Briefly, one volume of 9 % potassium alum (Sigma, aluminium potassium sulphate) was added an equal volume of protein solution at 0.5 mg/ml. Phenol red indicator was then added, and the solution neutralised by adding 1 M NaOH until the indicator turned pink. Proteins were allowed to precipitate at room temperature for 30 min. After this time, the precipitated protein was washed 3 times with PBS, until it became white. Mice were injected subcutaneously on day 0 with 100 µg, and boosted on days 28 and 35 with 50 µg. Blood was collected on day 42, and left overnight at 4°C prior to serum collection. 
3.11.2	Generation of monoclonal antibodies.  Mice were immunised on day 0 as above. Mice were then challenged intravenously with 1 µg of protein on days 28, 29 and 30. On day 31 mice were sacrificed and serum and spleens were collected.  Splenocyte suspensions were prepared by mashing the cells through a cell strainer. Cells were then fused at a 1:1 ratio with the myeloma cell line SP2 using PEG as a fusing agent. Cells were plated drop wise onto 96-well flat-bottom plates and incubated at 37ºC. On day 7 after fusion cells were screened against recombinant protein by ELISA. Positive wells were cloned by limiting dilution in 96-well plates.  Cells were screened and cloned a second time, and positive clones were grown and cryopreserved. (See Appendix 1 for further details). 

3.12	Monoclonal antibody purification.
Monoclonal producing cells were grown in 500 ml of RPMI supplemented with low IgG FCS (Invitrogen) in disposable bioreactors (BioVectra, VectraCell Single Use Bioreactor System). Cells were cultured for 3-4 weeks to allow maximum antibody production. Supernatants were harvested and spun down to remove cells. Monoclonal antibodies were purified using a Protein-G sepharose column and the ÄKTA prime system (Amersham Biosciences). Antibody was eluted using 1M Glycine pH=2.9 into neutralising buffer (TRIS pH=9). Purified antibodies were dialysed against PBS, filtered under sterile conditions and frozen for storage.

4	Molecular biology techniques. 
4.1	Cloning. 
Bm-MIF-1 and Bm-MIF-2 and the corresponding P2G mutants were amplified by PCR from adult cDNA libraries. A plasmid containing mouse-mif full coding sequence (a gift of Dr. C. Shoemaker and P. Skelly, Harvard Medical School) was used to amplify Mouse-MIF and the P2G mutant. 
Genes were amplified by PCR, 5 min denaturation at 94°C followed by 35 cycles 1 min 94°C, 1 min 55°C, 1 min 72°C, and a final extension step of 10 min 72ºC using Pfu polymerase (Promega). PCR products were resolved in 1% agarose gels and bands were purified using QIAquick Gel Extraction Kit (QIAGEN). Purified products were A-tailed using dATP and Taq polymerase at 70ºC for 30 min. A-tailed products were cloned into the pGEM-T cloning vector and transformed into E. coli JM109 (Promega). After colony screen and mini-prep purification (QIAprep Spin Miniprep Kit, QIAGEN), vectors were sequenced using DYEnamic at the university sequencing service. Following digestion with appropriate restriction enzymes, genes were sub-cloned into expression vectors (pET29c, or MIGR1), using the same protocol as for pGEMT cloning. 
Brugia MIF homologues had been previously cloned into pET29c for protein expression in our lab as described by Zang et al. (clones XX-004 to XX-007 as shown in table 5).
Table 2.3. Shows a list of primers used for cloning.
Table 2.4. Shows a list of vectors used.
Figure 2.1. Shows vector maps. 
Table 2.5. Show a list of the clones generated and used throughout this study. 

Table 2.3. Primers used for cloning. 
Primer (nt)	Sequence	Comments	Vector
Mouse mif-for(1-18)	5’-CATATGCCTATGTTCATCGTG-3’	Sense. Italic: NdeI site including start codon (Bold).	pET29c
Mouse mif-g-for(1-18)	5’- CATATGGGTATGTTCATCGTG-3’	Sense. Italic: NdeI site including start codon (Bold)Underlined: ProGly.	pET29c
Mouse mif-rev(346-322)	5’-CTCGAGAGCGAAGGTGGAACCGTTCC AGCC-3’	Common antisense primer. Italic: XhoI resctriction site.	pET29c
Bmmif-1-for(1-18)	5’-AGATCTCGCCACCATGCCATATTTTA CGATT-3’	Sense: Italic: BglII site. Underlined: Kozak sequence. Bold: start codon.	MIGR1
Bmmif-1-g-for(1-18)	5’-AGATCTCGCCACCATGGGATATTTT ACGATT-3’	Sense: Italic: BglII site Underlined: Kozak sequence. Bold: start codon. Underlined bold: ProGly.	MIGR1
Bmmif-1-rev(349-331)	5’-GTTAACTTATCCCAAAGTAGATCC-3’	Antisense: Italic: XhoI site. Stop codon in bold.	MIGR1
Bmmif-2-for(1-23)	5’-AGATCTCGCCACCATGCCGCTGATAA CGCTTGCTTC-3’	Sense: Italic: BglII site Underlined: Kozak sequence. Bold: start codon.	MIGR1
Bmmif-2-g-for(1-23)	5’-AGATCTCGCCACCATGGGGCTGATAA CGCTTGCTTC-3	Sense: Italic: BglII site Underlined: Kozak sequence. Bold: start codon. Underlined bold: ProGly.	MIGR1
Bmmif-2-rev(363-340)	5’-GTTAACTTATTTCTTCATAAGCTC TTTCAT-3’	Antisense: Italic: XhoI site. Stop codon in bold.	MIGR1
Mouse-mif-for(1-21)	5’-AGATCTCGCCACCATGCCTATGTTCAT CGTGAAC-3’	Sense: Italic: BglII site. Underlined: Kozak sequence. Bold: start codon.	MIGR1
Mouse-mif-g-for(1-21)	5’-AGATCTCGCCACCATGGGTATGTTCA TCGTGAAC-3’	Sense: Italic: BglII site. Underlined: Kozak sequence. Bold: start codon. Underlined bold: ProGly.	MIGR1





Table 2.4. List of cloning and expression vectors used.
Vector	Company/source	Description
pGEM-T	Promega.www.promega.com	T-cloning vector
pET29c	Novagen www.merckbiosciences.co.uk	Expression of His-tagged recombinant proteins
MIGR1	Gift from Alison Mitchie.	IRES-GFP retroviral expression vector.

Table 2.5. Clones generated and used throughout this study.
Clone no.	Organism	Gene	Modified	Vector/ RE site.
XX-004	B. malayi	MIF-1	No	pET29c Nde I/Xho I
XX-005	B. malayi	MIF-1G	Pro 2 -> Gly	pET29c Nde I/Xho I
XX-006	B. malayi	MIF-2	No	pET29c Nde I/Xho I
XX-007	B. malayi	MIF-2G	Pro 2 -> Gly	pET29c Nde I/Xho I
LP-013	Mouse	MIF	No	pGEMT
LP-014	Mouse	MIF	No	pET29c Nde I/Xho I
LP-015	Mouse	MIF-G	Pro 2 -> Gly	pGEMT
LP-016	Mouse	MIF-G	Pro 2 -> Gly	pET29c Nde I/Xho I
LP-017	B. malayi	MIF-1	No	pGEMT 
LP-018	B. malayi	MIF-1	No	MIGR1 Bgl II/Hpa I
LP-026	Mouse	MIF	No	pGEMT
LP-050	Mouse	MIF	No	MIGR1 Bgl II/Hpa I
LP-037	B. malayi	MIF-2	No	pGEMT
LP-054	B. malayi	MIF-2	No	MIGR1 Bgl II/Hpa I

4.2	Protein expression and purification.
Plasmid DNA was transformed into E. coli BL21(DE3) cells and grown overnight at 37°C in LB-agar plates containing 50 mg/ml of Kanamycin (LB-Kan). One single colony was picked and grown in 500 ml LB-Kan at 37°C in a shaker incubator until the optical density at 600nm (OD600) reached 0.5-0.8.  IPTG was added to a 1 mM final concentration and the incubation continued at 37°C for further 3 to 4 hours. At this time cultures were centrifuged at 7,000 g in a Sorvall high-speed centrifuge for 20 min. Bacterial pellets were resuspended in binding buffer (20 mM Na2HPO4/NaH2PO4, 0.5 M NaCl, 10 mM Imidazole) and sonicated on ice. Bacterial debris was removed by centrifugation at 11,000 g for 20 min, and supernatants were filtered through a 0.22 m (Millex-GV) Filter Unit (MILLIPORE). His-tagged proteins were then purified by affinity chromatography with a nickel-chelating column using the ÄKTA prime system (Amersham Biosciences). For the elution step the imidazole concentration was raised to 0.5 M. Proteins were dialysed against PBS to remove the imidazole.
Protein expression and purity were checked by SDS-PAGE and Coomassie staining (NuPAGE, Invitrogen). Protein concentrations were measured by Bradford assay (Pierce), with BSA used to make a standard curve. Figure 2.2 shows a representative example of the protein expression and purification protocol. To avoid LPS contamination all recombinant proteins were treated with 20 µg/ml of polymixin B-sulfate (Sigma) for 30 min at 37ºC prior to use in cellular assays.
4.3	Generation of retrovirus producing lines.
For transformation of mammalian cells plasmid DNA was purified using the QIAGEN Plasmid Midi Kit. To generate stable lines producing retrovirus, a ping-

pong system was used. First the dualtropic retrovirus packaging cell line PT67 was transiently transfected with MIGR1 clones using Effectine (QIAGEN) and cells were cultured for 48 h at 37ºC.  After 48 h supernatant from transfected PT67 (containing retroviral particles) was harvested and filtered through a 0.22µm filter to remove dead cells. Retroviral supernantat was then used to transduce the GP+E.86 packaging cell line by spin infection. Polybrene was added to the retrovirus-containing supernatant, at an 8 µg/ml final concentration to help infection. GP+E.86 cells were cultured for 48 h when cells were collected and sorted by GFP positive selection.  Retroviral producing lines were routinely maintained in culture for infection of primary cells. Appendix 2 provides more detailed protocols for these steps.
4.4	Retroviral transduction of target cells. 
Bone marrow cells were obtained by flushing the bones, and cells were cultured for 48 h in DMEM containing 10 ng/ml of rm-SCF and 20ng/ml rm-IL-3 (R&D) in 6-wells plates. On the same day 1x105 GP+E.86 cells were plated in 6-well plates and allowed to produce retrovirus for 48 h. An additional plate with 2.5x104 GP+E.86 cell was grown for the second infection. On day 2 and 3 BM cells were spin-infected with retroviral-containing supernatant supplemented with 7.5µg/ml polybrene (Sigma) at 699 g in a bench-top Sorvall centrifuge for 1 hour at room temperature. After the second infection cells were supplemented with media containing cytokines, and the cells were cultured for a further 48 to 96 hours to allow maximum gene integration. Infection efficiency was assessed by flow cytometry. 
4.5	RNA extraction.
For RNA extraction 1 ml TRIzol (Invitrorgen) was added to 1x106 cells. RNA was then purified following the manufacturer’s instructions. Briefly, 200 µl chloroform was added per 1 ml TRizol, and the mixture incubated 10 min at room temperature. Suspensions were centrifuged 15 min at maximum speed (10790 g) on a bench top microcentrifuge at 4ºC. The aqueous phase was collected, and RNA was precipitated by addition of 500 µl isopropanol for every 1 ml initial TRizol. RNA pellets were washed with 70 % ethanol and allowed to dry.  After resuspension in 20 µl water, RNA was treated at 37ºC for 30 min with DNAse I (Ambion) to eliminate genomic DNA contamination. The RNA concentration was determined by OD measurement using a Spectropore (Eppendorf) at A260 (1 A260 unit RNA = 40 g/ml H2O). The purity was determined by the A260/A280 ratio, and by gel electrophoresis (1% agarose) and ethidium bromide staining (0.4 g/ml) of the RNA.
4.6	Reverse transcription. 
1 g of RNA was used for the synthesis of first strand cDNA. Each reaction (20 l) contained 1 mM of each dNTP (Stratagene), 0.5 g oligo dT (Promega), 1 U RNAse inhibitor (Promega) and 50 U MMLV reverse transcriptase (Stratagene), in 1x reaction buffer (Stratagene). The conditions used for reverse transcription were; 20C for 10 minutes, 37C for 1 hour and 99C for 5 minutes.
4.7	Real time PCR.
The relative expression of AAMf markers was measured by real-time PCR using Light Cycler (Roche Molecular Biochemicals) or Chromo4 (Genetic Research Instrumentation Ltd.) qPCR machines.  b-actin, HPRT or GAPDH were used as housekeeping reference genes.  For Light Cycler PCR amplifications were carried in 10 l, containing 1 l cDNA, 4 mM MgCl2, 0.3 M primers and the LightCycler-DNA SYBR Green I mix (Roche). Ym-1 was amplified using the following conditions, 30 s denaturation at 95°C, 5 s annealing of primers at 63°C and 12 s elongation at 72°C, for 40–60 cycles. The fluorescent DNA binding dye SYBR Green (Roche) was monitored after each cycle at 85°C. For all other primers, the annealing temperature was 55C and the monitoring of SYBR green fluorescence was performed at 86C.
For Chromo4 PCR reactions were carried in 10 µl containing 1 µl cDNA, 0.3 µM primers and SYBR Green Supermix-UDG (Invitrogen).  The following conditions were used: 15 min hot start at 95ºC, followed by denaturation at 95ºC for 20 s, primer annealing at 55ºC for 20 s and elongation at 72ºC 20 s for 50 cycles. The fluorescent DNA binding dye SYBR green was monitored after each cycle at 80ºC. 
Table 2.6 shows a list of the primers used for real-time PCR.  The same primers were used for both real-time PCR systems. 

5	Statistical analysis.
For comparison involving more than two data sets, data were transformed (log10) and ANOVAs performed if transformation allowed equal variances. When p-values were less than 0.05, results were considered significant and Bonferroni post-test were performed for the pairs of data sets of interest. All calculations were performed using GraphPad Prism software. 
































Macrophage activation by MIF homologues.
1	Introduction. 
During infection macrophages are recruited to the site of inflammation, where they become activated through different pathways depending on the microenvironment they encounter (Mills et al., 2000).  Bacteria and intracellular parasites induce a pro-inflammatory type 1 environment (IFN-g, TNF-a) that triggers activation of intracellular pathways leading macrophages to produce pro-inflammatory cytokines IL-6, TNF-a, IL-12 and the production of NO (Bonecchi et al., 1998).  On the contrary, helminth parasites and allergic reactions create a type 2 environment characterised mainly by IL-4 and IL-13, these type 2 cytokines induce up-regulation of a different set of genes through the IL-4Ra pathway and Stat-6 phosphorylation, leading macrophages to an alternative activated phenotype characterised by the production of Ym-1 (Nair et al., 2003) and Arginase-1 (Hesse et al., 2001), and their suppressor capacity (Loke et al., 2000b). 
Moreover, type 1 and 2 stimulation of macrophages induce different surface markers; whereas IFN-g up-regulates surface MHC-II (Steeg et al., 1982), both IL-4 and IL-13 stimulation favour expression of Scavenger and Mannose Receptors (Stein et al., 1992). 

To study the effects that host and parasite MIF have on macrophages, a series of in vitro experiments were designed (Fig. 3.1). 

Day 7 bone-marrow derived macrophages were treated with MIF and the activation state of the macrophages was analysed by flow cytometry, ELISA and RT-PCR.  The starting hypothesis was that while mouse MIF will promote a pro-inflammatory response, Brugia MIF will activate macrophages to an alternative phenotype inducing an anti-inflammatory environment beneficial for the parasite.
Because macrophages are a widely heterogeneous population (Gordon and Taylor, 2005), for some experiments macrophages were obtained from different sources. Thioglycollate elicited macrophages were used because they are easily isolated and resemble activated peritoneal macrophages; splenic macrophages were purified ex-vivo as an example of tissue resident macrophages; whereas bone marrow-derived macrophages behave like blood circulating monocytes.

Interestingly, the results indicate that mouse and parasite MIF do not differ in their polarising ability, and that the macrophage phenotype is dependent on the cytokine environment. Within this context, however, when IL-4 is present, MIF enhances alternative activation and the macrophage suppressive capacity. 

2	Results.
2.1	Classical activation of macrophages by MIF homologues.
2.1.1	MIF induces down-regulation of surface class II.
The first approach taken was to test the direct effect of recombinant proteins on macrophage surface expression. Day 7 bone marrow macrophages were therefore treated with recombinant protein, which had been pre-treated with polymixin-B to neutralise any possible LPS contamination. After 24 h, flow cytometry was used to assess cell activation, staining with specific antibodies to MHC-II and co-stimulatory molecules CD40 and CD80, CD86. A slight reduction in MHC-II expression was observed after treatment with mouse-MIF or Bm-MIF-2, while Bm-MIF-1 had no effect on MHC-II levels. None of the treatments affected expression of the other surface markers analysed. Figure 3.2 shows representative data from one experiment.
2.1.2	MIF homologues induce pro-inflammatory cytokine production by macrophages.
The next analysis was of cytokines released by day 7 bone marrow-derived macrophages, thioglycollate-elicited macrophages and ex-vivo purified macrophages in response to overnight incubation with each of the recombinant MIF proteins or their correspondent tautomerase-deficient mutants. After 24 h supernatants were harvested and cytokine levels were measured by sandwich ELISA. Mouse-MIF and to a lesser extent Bm-MIF-2 but not Bm-MIF-1 induce production of pro-inflammatory cytokines IL-6 and TNF-a (Fig 3.3).















Further analysis of cytokine production, showed no difference between host and parasite MIF in stimulating production of IL-10 or IL-12p40. BM-derived macrophages were treated with increasing concentrations of each of the recombinant proteins (1, 5, and 10 µg/ml) overnight, and cytokine production was measured. For each MIF homologue, IL-10 production increased in a dose-dependent manner (Fig. 3.4a). Although IL-10 production elicited by Bm-MIF-2 was slightly higher, this was not significantly different from Bm-MIF-1 or mouse-MIF. On the other hand, all three homologues induced equivalent amounts of IL-12p40 independent of the amount of protein used to treat macrophages (Fig. 3.4b). Again, only in the case of mouse MIF was the stimulatory effect dependent on tautomerase activity, as Bm-MIF-1G and Bm-MIF-2G had the same effect as the intact proteins while mouse-MIFG failed to induce IL-10 and induced lower amounts of IL-12p40 (Fig. 3.4). 
2.1.3	MAP kinase pathway activation by MIF homologues.












level than mouse-MIF (Fig 3.5). Bm-MIF-1 failed to activate this pathway at all in this assay.
2.1.4	MIF homologues induce cytokine production in a CD74 independent way.
(CD74 deficient cells were provided by Elisabeth Bikoff)
The invariant chain of MHC-II (CD74) has been reported as one possible receptor to mouse-MIF in macrophages. Several works by Richard Bucala’s group have shown that binding of MIF to CD74 is essential for MAP kinase phosphorylation. To assess whether Brugia MIF homologues act through the same receptor, macrophages from CD74-deficient mice (In-1 –/– (Bikoff, 1992)) were used. WT (R2G) and CD74 –/– day 7 BM-derived macrophages were treated with increasing amounts of rMIF and cytokine production was measured by ELISA (Fig. 3.6). Surprisingly no difference was observed between WT and deficient mice in cytokine induction by MIF, and in fact CD74-deficient macrophages showed higher levels of cytokine production (particularly IL-12p40, Fig. 3.6c).  
In a parallel experiment, MAP kinase phosphorylation was studied. Macrophages from WT and deficient mice were treated with 10µg of rMIF, after 20 min cells were collected and lysed for western blot analysis. As observed for cytokine expression, no difference was detected between WT and CD74 –/– cells  (Fig. 3.7).














macrophages behaved the same as C57BL/6-derived ones. Furthermore, in experiments with DC or bone marrow (chapters 4 and 5) MIF had the same effect regardless of the strain of mouse used. 
Another possible explanation is that experiments in figures 3.2, 3.3 and 3.5 were performed with a different protein preparation than that used in experiments in figures 3.4, and 3.6-10. However, the Bm-MIF-1 batch used in the first set of experiments was biologically active as it was able to activate macrophages in an alternative way (see below), so incorrect synthesis or folding of this batch does not account for the differences observed. Another possible explanation is a difference in the bacterial contaminants between protein preparations. To discount this possibility, and to confirm that macrophage activation is MIF-specific, recombinant MIF was removed from the protein preparation using specific monoclonal antibodies, and MIF-depleted fractions were then used to stimulated macrophages. 
2.1.5	MIF depletion from the recombinant preparations abolishes cytokine production.















mouse-MIF fractions were also subjected to a second round of precipitation to assure equal treatment for all the preparations. After precipitation of the immunocomplexes, depleted fractions were used for in vitro experiments (Fig. 3.8b). BM-derived macrophages were treated with a volume equivalent to 10 µg of initial protein, and cytokine release was measured by ELISA. Both IL-6 and IL-10 production induced by MIF were completely abolished when recombinant protein was depleted (Fig. 3.8c). 
2.1.6	CD74 expression in BM-macrophages.
The results observed with CD74 deficient cells were quite unexpected and led us to analyse CD74 expression in BM macrophages. CD74 deficient cells express reduced levels of MHC-II at the surface (Koonce and Bikoff, 2004) so levels of CD74 and MHC-II expression were first analysed. BM-macrophages used in these studies were found to have very low levels of surface class-II (Fig. 3.2), and it was necessary to analyse BM-DC in comparison as a strong positive control for MHC-II expression. Bone marrow cells from WT or CD74 deficient mice were cultured with M-CSF (L929 media) or GM-CSF (X63 media) for 7 days; at this time cells were stained for intracellular CD74 and surface MHC-II.  Figure 3.9 shows flow cytometry plots gated on F4/80 for macrophages and CD11c for DCs. WT DC co-express high levels of MHC-II and CD74, whereas as expected in CD74 deficient cells class II expression drops by 5 fold and no CD74 can be detected. In contrast, MHC-II levels in both WT and CD74 deficient macrophages are extremely low. 
Our observation that both WT and CD74-deficient macrophages respond equally to MIF stimuli may be explained if resting, day 7 macrophages do not in fact express sufficient levels of CD74 for it to act as a receptor for MIF. Notably, MIF was first

described to bind CD74 in IFN-g treated THP-1 monocytes (Leng et al., 2003). We therefore treated BM-derived macrophages with MIF in the presence or absence of IFN-g and cytokine production was measured (Fig. 3.10). Cytokine production induced by MIF was independent of CD74 expression, not only as previously described in resting day 7 macrophages, but also in those co-stimulated with IFN-g. Although CD74 was previously reported to play an important role in MIF-induced proliferation via MAPK activation, its role in cytokine production has not been previously studied. Hence, it is possible that MIF may be inducing cytokine production and MAPK activation through different pathways.
 
These results, taken together, indicate that both filarial and mouse MIF induce cytokine production from macrophages, and that this effect is independent of CD74.

2.2	Alternative activation of macrophages by MIF homologues.




2.2.1	MIF homologues enhance alternative activation of macrophages induced by IL-4. 
Despite the ability of Bm-MIF-1 to induce alternative activation markers on macrophages in vivo (Falcone et al., 2001), no such up-regulation was detected when incubating macrophages with increasing concentration of parasite MIF, raising the question of whether other factors might be needed. Alternative activation was first described as the phenotype induced by Th-2-driving cytokine IL-4 (Stein et al., 1992) and it was subsequently demonstrated that expression of Ym-1, Fizz-1 and Arginase-1 are strongly dependent on IL-4 (Gordon, 2003). For this reason, macrophages were simultaneously cultured with MIF and increasing concentrations of IL-4. After overnight treatment, cells were collected in TRIzol for RNA extraction, and expression levels of Ym-1, Fizz-1, Arginase-1 and iNOS were measured by real-time PCR. Both GAPDH and b-actin were used as reference genes showing equivalent results. 
As can be seen from Figure 3.11, IL-4 induces expression of alternative activation markers in a dose-dependent manner (expression is shown as fold increase over media alone). Although no MIF homologue was able to directly induce expression of alternative activation markers, we observed that MIF could synergise with IL-4, as addition of 10 µg of rMIF greatly enhanced alternative activation induced by IL-4 (Fig. 3.12). 








compared to 6.1 for Bm-MIF-1 and 7.4 for Bm-MIF-2. No significant rise was seen with Fizz-1 which was strongly induced by IL-4 alone. We also observed differences in the ability of the tautomerase-deficient mutants to synergise with IL-4. Bm-MIF-1G and mouse-MIFG were unable to enhance IL-4 effects, while Bm-MIF-2G induced a very similar effect to Bm-MIF-2. 
Finally, while mouse-MIF induced some expression of iNOS in the absence of other stimuli, filarial homologues did not enhance iNOS expression above media levels. Furthermore, iNOS expression by mouse-MIF was abolished in the presence of IL-4.
As optimal alternative activation, assessed by up-regulation of gene expression, was achieved at 20ng/ml of IL-4, this concentration of IL-4 was chosen for subsequent experiments.
2.2.2	MIF homologues induce up-regulation of IL-4Ra.




Analysis of IL-4Ra expression revealed that all three MIF homologues significantly up-regulated IL-4Ra mRNA expression even in the absence of IL-4. Although IL-4 alone did not raise IL-4Ra levels, the combination of both ligands greatly increased expression levels in all cases (Fig. 3.13.c).  
2.2.3	IL-4 treatment reduces MIF-induced pro-inflammatory cytokine production.
To further assess the effect of IL-4 in macrophage activation by MIF, macrophages were treated with 10 µg/ml of recombinant MIF in the presence or absence of 20 ng/ml of IL-4 and supernatants were harvested for cytokine measurement by ELISA. (Fig. 3.14). As in previous experiments, MIF stimulated cytokine production by macrophages after 24 h. Although IL-4 did not itself induce cytokine production, it did alter the balance of cytokines made in response to MIF. Thus, IL-6 production was significantly decreased when cells were co-treated with IL-4, and most dramatically, IL-12p40 production was completely inhibited in the presence of IL-4. Notably, IL-10 production was not altered under the same circumstances.
2.2.4	MIF homologues synergise with IL-4 to suppress EL-4 proliferation. 




EL-4 cells incubated with PBS-treated macrophages, or macrophages that had been pre-treated with any of the MIF recombinants or IL-4 alone, proliferated normally. However, when macrophages had been exposed to a combination of IL-4 with any of the MIF homologues, they were render highly suppressive, sharply reducing EL-4 proliferation. Up to 75% suppression was observed when macrophages had been exposed to IL-4 plus Bm-MIF-1, Bm-MIF-2 or mouse-MIF, and a lower degree when macrophages had been treated with the tautomerase-deficient MIF mutants (Fig. 3.15). These observations strongly support the hypothesis that parasite MIF play a role in alternative activation of macrophages, and uncover a new aspect of mammalian MIF, as mouse-MIF is also able to enhance IL-4 induced alternative activation.

3	Discussion.











systems.  In the hypo-inflammatory phase that follows septic shock, MIF restores production of TNF-a and IL-6, which in turn improves resistance to bacterial superinfection (Pollak et al., 2005). On a different setting, treatment of macrophages with recombinant MIF induces L. major killing through the production of TNF-a and NO (Jüttner et al., 1998).

Filarial MIFs were first characterised by their homology with the mammalian protein (Pastrana et al., 1998; Zang et al., 2002). Functional studies revealed that Bm-MIF-1 has the ability to inhibit random migration of human macrophages (Pastrana et al., 1998), and that both Bm-MIF-1 and -2 induce cytokine production by these cells (Zang et al., 2002). In addition, the potential role of Bm-MIF-1 in alternative activation of macrophages during filarial infection was suggested by the observation that in vivo injection of Bm-MIF-1 induced a population of macrophages that expressed Ym-1 (Falcone et al., 2001). 
These different observations, lead us to hypothesise that while mammalian-MIF is a potent pro-inflammatory factor, filarial homologues will activate macrophages to an alternative phenotype that contributes to counter inflammation during B. malayi infection.

The initial analysis was of the direct effect of filarial MIF homologues on macrophages, in comparison to the host protein. Although slight down-regulation of MHC-II molecules was observed when treating macrophages with mouse-MIF or Bm-MIF-2, Bm-MIF-1 did not have this effect; furthermore neither protein had an effect on co-stimulatory markers. These data suggest that neither Brugia nor mouse-MIF significantly alter macrophage surface phenotype.
Further analysis showed that MIF stimulation induced cytokine production by 3 different types of macrophages. Differences were, however, observed in the levels of cytokine production between host and parasite proteins. Mouse-MIF induced higher levels of TNF-a, whereas IL-10 production was higher following stimulation with Brugia MIF homologues, and all three proteins induced equivalent levels of IL-6 and IL-12p40. Moreover, IL-4 co-treatment decreased IL-6 and IL-12 production, but did not alter IL-10. On the other hand, co-treatment with IFN-g enhanced IL-6 and IL-12p40 production by MIF and decreased IL-10. Together these data suggest that while in an inflammatory environment MIF contributes to the inflammation process, in a type 2 situation MIF may skew cytokine responses towards anti-inflammation.  The observation that mouse-MIF induces the highest levels of TNF-a, while Brugia homologues induce higher levels of IL-10, lead me to suggest that parasite MIF may play a role in counter-regulating inflammation. 

One of the features of mammalian MIF is its ability to induce cell proliferation and survival through the activation of MAPK pathways (Leng et al., 2003). Although none of the recombinant MIFs induced macrophage proliferation in our experimental setting (data not shown), we assessed MIF capacity to activate MAPK phosphorylation. As found for cytokine production, different levels of MIF-induced phosphorylation were observed in each homologue. While mouse-MIF is a potent MAPK activator neither filarial MIF strongly induced phosphorylation, although some phosphorylation of ERK1/2 and p38 was observed after 2 h incubation with Bm-MIF-2.

MIF activation of MAPK pathways has been shown to be dependent on binding of the putative MIF receptor CD74, which is the membrane bound form of MHC-II invariant chain. Thus the effects of MIF on wild-type and CD74-deficient cells were compared, measuring cytokine production, which is most clearly induced with either parasite or host MIF. To our surprise no differences were observed, with all three MIF homologues inducing cytokine production in both wild-type and CD74–/– macrophages to equivalent levels. Indeed, CD74–/– cells showed enhanced production of IL-12p40 in response to MIF proteins.
 
CD74 staining of BM-derived macrophages revealed that unlike DC, wild type macrophages express very low basal levels of this protein, and only minor differences were observed between WT and deficient cells suggesting that there may be insufficient surface CD74 to act as a receptor in this cell type. 
CD74 binding to MIF was originally described using IFN-g treated macrophages. IFN-g up-regulates MHC-II in macrophages (Steeg et al., 1982), hence MIF activity might be dependent on IFN-g-mediated class II induction, in order to expose higher CD74 in the membrane. To test this hypothesis, macrophages were simultaneously treated with IFN-g and MIF, and cytokine production measured. All three MIF homologues induced cytokine release in wild-type and CD74-deficient macrophages independently of IFN-g treatment.  It is possible that pre-treatment with IFN-g instead of simultaneous treatment with MIF might show different results. Further analysis of macrophage activation by MIF in the presence of IFN-g will help elucidate this and other questions, however with these observations we conclude that in our experimental setting, MIF effects are independent of CD74. 

The initial hypothesis was that whereas mouse-MIF induces inflammation through classical activation of macrophages, filarial MIF homologues would favour alternative activation. A possible link between Bm-MIF-1 and alternative activation in vivo has previously been indicated (Falcone et al., 2001), and both Bm-MIF-2 and mouse-MIF induce macrophage recruitment and expression of alternative activation markers when injected in the peritoneal cavity of mice (Gregory et al, unpublished observations).  Despite these observations in vivo, neither Bm-MIF nor mouse-MIF can induce in vitro up-regulation of macrophage alternative activation markers. Alternative activation of macrophages by filarial parasites is strongly dependent on IL-4, so one explanation for the differences observed between in vivo and in vitro observations might be the presence of IL-4 in vivo.  The results did indeed support this idea, as MIF showed marked synergy with IL-4, enhancing the expression of alternative activation markers induced by IL-4 alone, as well as synergising to render macrophages suppressive. Moreover, MIF alone induced IL-4Ra expression, and IL-4Ra levels were strongly up-regulated when IL-4 was present in the media.

Taken together these data suggest that macrophage activation by MIF homologues is dependent on the cytokine environment.  Although more extensive studies will be needed to elucidate the relationship between MIF and INF-g, we have shown that MIF and IL-4 act together to induce alternative activation of macrophages, a situation more likely to happen during the strong type 2 environment induced by B. malayi infection.  Furthermore, we have shown that MIF homologues induce slightly higher levels of IL-10 production by macrophages than does mouse-MIF, suggesting filarial proteins favour a more anti-inflammatory phenotype. IL-10 is not only produced by AAMf but it contributes to this alternative activation by up-regulating IL-4Ra increasing IL-4 responsiveness as a result (Lang et al., 2002). It is possible thus that MIF-induced IL-10 might be acting in an autocrine way. Further experiments with IL-10 blocking antibodies, or IL-10 deficient cells will help elucidate whether MIF homologues enhance alternative activation in a direct manner or through IL-10 induced signalling. (MacDonald et al., 1998). 
Finally, macrophage response to the different MIF homologues suggest that parasite and host MIF might be inducing different intracellular responses. The observation that MIF induction of IL-6 and IL-10 production is differentially regulated in the presence of IL-4 suggests distinct signalling pathways. Moreover, mouse-MIF induces higher levels of Arginase-1, whereas filarial MIF homologues induce the highest Ym-1 in combination with IL-4, further supporting the idea of differential intracellular signalling. 

In conclusion, whereas MIF homologues induce macrophage activation towards an inflammatory-like phenotype in the absence of other stimuli, in combination with IL-4 both host and parasite MIF contribute to the macrophage alternative activated state characteristic of filarial infection. The possible implications of these observations are further discussed in chapter 7, in relation with the effect that MIF has on other APC and the implications this might have in vivo. 
Chapter 4
Dendritic cell activation by MIF homologues.
1	Introduction.
Dendritic cells are one of the major types of antigen presenting cell with the unique capacity to sample sites of pathogen entry, respond to microbial signals and trigger T cell responses. Tissue-resident immature DC act as sentinels that can up-take and process antigen but are not yet able to activate T cells. Exposure to exogenous or endogenous antigens triggers dramatic changes in DC maturation, shown by the up-regulation of surface MHC class II and the co-stimulatory molecules CD40, CD80 and CD86. In this activated state, DC are now competent to initiate immune responses by activating T helper cells (Shortman and Naik, 2007).
It is now well characterised that bacterial components and intracellular parasites interact with DC through TLR receptors to trigger DC activation, IL-12 production and the initiation of type 1 responses. In contrast, how DC initiate the type 2 responses characteristic of helminth infections is not as well understood (Sher et al., 2003).
 Bone marrow-derived DC exposed to helminth derived products display relatively little change in phenotype, despite the fact that these DC induce strong antigen specific Th2 responses when transferred in vivo (Balic et al., 2004, MacDonald, 2002 #148).  Furthermore, DC exposure to helminth antigens impairs subsequent activation by LPS, suggesting these helminths can actively alter DC function even in the presence of TLR ligands. 


Because parasite-derived MIF might exert an important influence on DC functions, and because DCs express relatively high levels of CD74 (chapter 3), the role of MIF during DC activation was investigated. A series of in vitro studies were performed using murine bone marrow and human PBMC derived DC and each of the recombinant MIF homologues previously described. First, DC were incubated overnight and their activation state analysed by flow cytometry for surface markers. DC cytokine production in response to MIF stimulation was measured by ELISA. To assess whether MIF might act, like some helminth antigens, to interfere with pro-inflammatory stimuli, cells were pre-treated with MIF protein, followed by treatment with bacterial LPS, a strong TLR ligand, or mammalian MIF (Fig. 4.1). Finally, to study DC-driven T cell activation, MIF-treated DC were transferred into mice and the character of immune responses elicited was analysed by antigen specific re call assays.
2	Results. 
2.1	MIF effects on bone marrow-derived dendritic cells.
2.1.1	Mouse MIF but not Bm-MIF-1 or -2 induces up-regulation of DC activation markers in a dose-dependent manner. 
The initial analysis of DC responsiveness to MIF was carried out by flow cytometry for surface markers which reflect the cell activation state. Day 7 bone marrow derived DCs were treated with a range of polymixin-treated MIF recombinant proteins, and the corresponding tautomerase deficient mutants (MIF-G), while control cells received an equivalent volume of PBS treated with polymixin. Staining for surface markers was performed 24 h later. Only a modest effect was observed in cells treated with mouse-MIF; in which MHC-II and CD40 expression showed evident up-regulation (Fig. 4.2.a). Neither Bm-MIF-1 nor Bm-MIF-2 induced more than a slight change. Up-regulation of surface markers increased in a concentration dependent manner for mouse-MIF, and was diminished in the cells treated with tautomerase deficient proteins (Fig. 4.2.b). 

2.1.2	Mouse-MIF and Bm-MIF-2 induce inflammatory cytokine production but Bm-MIF-1 does not.
The degree of DC activation was then analysed at the level of cytokine production. The pattern seen was consistent with the surface marker data in that mouse-MIF stimulated DCs to produce inflammatory cytokines, IL-6, IL-12p40 and TNF-a with a smaller effect evident with Bm-MIF-2 (Fig 4.3). Bm-MIF-1 failed to stimulate any cytokine release. Cytokine release increased with dose and was dependent on tautomerase activity, as cytokine production was lower when cells were treated with MIF-G mutants (Fig 4.3 hatched bars). IL-10 and IL-12p70 were not detected after any of the treatments.













Bm-MIF-1 is only a weak DC stimulator, able to induce cytokine expression under some circumstances, but without secretion.  
2.1.3	DC activation by MIF homologues is partly dependent on endogenous MIF.
It has previously been reported that Brugia MIF homologues induce secretion of endogenous MIF from human monocytes (Zang et al., 2002), raising the question of whether parasite MIF may act indirectly by inducing mouse-MIF. Direct measurement of host MIF using sandwich ELISA was confounded by cross-reactivity of anti-MIF antibodies with each of the recombinant proteins, as no endogenous mouse-MIF specific assay was available. We therefore studied the effect of MIF homologues on DC taken from mice with a gene-targeted null allele for MIF.  BM-derived DC from 129 WT mice and MIF –/– mice were treated with 10 µg/ml of protein overnight, and cytokine production was measured by ELISA. 
Although IL-12p40 production was equivalent in WT and deficient cells, mouse-MIF induction of both IL-6 and TNF-a was reduced in the absence of endogenous MIF (Fig. 4.5), suggesting either that MIF cytokine induction is partly dependent on endogenous MIF release or that DC differentiating in a MIF-free environment do not acquire the ability to make optimal IL-6 and TNF-a responses.
2.2	MIF effect on subsequent DC activation. 
The experiments described above show that filarial MIF homologues have very little effect on DC activation compared to the mammalian cytokine. Previous studies have shown that pre-incubation of DC with helminth-derived antigens impair DC activation by LPS. For example, BM-DC treated with N. brasiliensis ES (NES) for 6 hours, show a sharply inhibited IL-12p70 response to LPS (Balic et al., 2004). To 

address whether MIF modulates DC activation by blocking responses to other maturation stimuli, DC were pre-treated with MIF followed by incubation with a second stimulus, before DC activation was analysed.
2.2.1	Pre-incubation of DC with MIF does not inhibit LPS-mediated activation.
DCs respond strongly to LPS by producing inflammatory cytokines such as IL-12. Pre-exposure to LPS or other TLR ligands desensitises cells, diminishing their ability to respond to subsequent LPS stimulation (Fan and Cook, 2004; Peck et al., 2004). 
We pre-incubated DC for 6 h with MIF proteins, after which time cells were washed to eliminate traces of polymixin B and 1 µg/ml of LPS was added. Cells were incubated for a further 18 h and activation was measured by flow cytometry and ELISA. It was established that MIF pre-incubation did not alter activation induced by LPS, as seen by both surface marker up-regulation (Figure 4.6a) and cytokine production (Figure 4.6b).
LPS induces up-regulation of both MHC-II and CD40 after 18 h (orange thick line) compare to unstimulated cells (solid grey). Similar responses to LPS stimulation were observed in cells pre-stimulated with either parasite or mammalian MIF (Fig 4.6a: solid orange: LPS alone, compared to pre-stimulation with Bm-MIF-1: red thick line or mouse-MIF: purple thick line). 
2.2.2	Pre-exposure of DCs to MIF does not affect their subsequent stimulation by mouse-MIF.










predicted that Bm-MIF homologues would co-localise with endogenous mammalian MIF, creating the opportunity for MIF to block or otherwise interact with host MIF functions. To assess the hypothesis that Brugia MIF homologues interfere with mouse-MIF-induced activation, pre-stimulation and co-stimulation experiments were performed. 












Similar results were observed when analysing cytokine production. Proteins were sequentially added (6h pre-treatment followed by 18h mouse-MIF addition, Fig. 4.8a) or added at the same time (increasing concentration of rMIF plus 10 µg/ml mouse-MIF for 24h, Fig. 4.8b). Although there is a general trend for increased cytokine release from cells receiving two MIF stimuli, neither of the parasite MIF homologues studied showed a consistent effect on cytokine production induced by mouse-MIF. 

From these observations we can conclude that neither the parasite MIF homologues, nor the host cytokine, have a blocking effect on subsequent stimulation of DC, suggesting that MIF is not affecting TLR-dependent or mouse-MIF-induced signalling in this cell population. 

2.3	Effect of MIF on human PBMC derived DC.
(Human DC experiments were performed in Leiden University Medical Centre in collaboration with Dr. K. Augustijn who provided recombinant Human-MIF proteins)

To study the effect of MIF proteins on human DC, PBMC were isolated by CD14 positive selection of Buffy coats and cultured in the presence of GM-CSF and IL-4. Day 7 DC were treated with recombinant MIF protein and activation was analysed by flow cytometry and ELISA. Human-MIF as well as mouse-MIF was used for comparison between host and parasite proteins. 
2.3.1	Mammalian MIF induces stronger activation of human DC than its filarial homologues.
DC were incubated overnight with either 3 or 10 µg/ml of each recombinant protein, and activation state was analysed by flow cytometry staining for surface HLA-DR (class II) and CD40. Although no significant changes were observed in HLA-DR expression, both mammalian MIF homologues induced up-regulation of surface CD40 (Fig. 4.9 shows histograms of 10 µg/ml treatments). Both Bm-MIF-1 and -2 induced a slight sift in CD40 levels, but in neither case reached human-MIF activation levels (Fig. 4.9 right panel, top histograms). 

Analysis of the supernatants by ELISA corresponded with the flow cytometry results observed by FACS as both mammalian MIF proteins activated DC to produce inflammatory cytokines (Fig. 4.10). Confirming previously published data on human monocytes (Zang et al., 2002), both Bm-MIF-1 and -2 were able to induce IL-6 and IL-8 from human dendritic cells, although at a lower level than either mammalian protein.
2.3.2	Pre-stimulation of human DC with MIF homologues does not affect subsequent stimulation by human-MIF.





mouse-MIF did not affect further mouse-MIF induction (data not shown). These results corroborate the effects observed with murine bone marrow-derived DC which are activated by mouse-MIF but not filarial homologues, thereby validating the use of mouse DC in the majority of our studies. 

2.4	MIF effect on DC mediated T cell responses.
To study the effect of MIF on the ability of DCs to drive T cell responses, in vivo transfer experiments were performed. BM-derived DC were exposed to MIF and/or ovalbumin antigen, and intraperitoneally transferred into mice. 7 days later spleens were harvested and antigen-specific responses were analysed by re call assays (Fig. 4.12). 
2.4.1	MIF pulsed DCs failed to mount MIF specific responses.





2.4.2	MIF treatment does not alter DC capacity to present OVA peptide. 





Although the role of MIF in macrophage activation has been thoroughly studied, less attention has been paid to the effect of this cytokine on other antigen presenting cell populations such as dendritic cells. DC are known to release MIF (Morelli et al., 2001; Murakami et al., 2002; Popa et al., 2006), but only 2 studies refer to the direct effect of MIF on this cell type.  Murakami et al showed that MIF stimulation induced production of IL-1 and IL-8 by peripheral blood human DC. In a different study, Stavitsky et al showed up-regulation of B7.2 and ICAM-1 after rMIF treatment of BM-derived DC. 

In the present study MIF homologues are shown to have different abilities to activate DC. Mammalian-MIF induces up-regulation of surface markers (MHC-II, CD40) and pro-inflammatory cytokine production (IL-6, TNF-a, IL-12p40) in both murine and human derived DC. In contrast, filarial homologues differ in their activation capacity. Bm-MIF-2 but not Bm-MIF-1 induced slight up-regulation of CD40 and cytokine production on BM-DC, but at levels well below those achieved by the mouse protein.

It has been previously reported that helminth products can block LPS-mediated DC activation in a TLR-4 dependent manner (Kane et al., 2004). On the other hand, it is known that MIF induces up-regulation of TLR-4 (Roger et al., 2001).  For these reasons, we investigated whether MIF homologues interfere with LPS activation of DC. Cells that were pre-treated with either mammalian or filarial MIF prior to LPS stimulation showed no changes compared to LPS stimulation alone, as seen by both cytokine production and surface marker expression. These results lead to two conclusions; first, in this setting MIF does not enhance LPS-induced DC activation and therefore we can say there is no further TLR-4 up-regulation; and second, DC activation by MIF homologues is unlikely to be a result of LPS contamination in the recombinant protein preparations, as this would have lead to LPS tolerance and a decreased response in subsequent LPS-activation.

Our next hypothesis was whether filarial MIF homologues, by using the same receptor as host MIF, might interfere with or block the effect of mouse-MIF, despite not being strong stimulants themselves. We treated DC with a combination of parasite MIF and host MIF in a sequential or concurrent manner.  Neither pre-treatment nor co-treatment of parasite or mouse-MIF with mouse-MIF showed significant differences compared to cells that have been treated overnight with mouse-MIF alone. 
These data suggest either that filarial MIF does not bind the same receptor as mouse-MIF, or that this binding does not block further MIF interactions, as pre-treatment with mouse-MIF did not affect subsequent mouse-MIF stimulation.  We have shown in our macrophage studies that MIF-induced cytokine production is independent of CD74 expression (putative MIF receptor), so an explanation of filarial MIF inability to block mouse-MIF DC activation is that this effect is not receptor mediated and even if Bm-MIF binds CD74 (or other receptors) this would not alter the effect of MIF effect on DCs. 

Brugia malayi is a filarial parasite of humans and previous studies with Brugia MIF homologues have been conducted on PBMC derived monocytes (Pastrana et al., 1998; Zang et al., 2002). To confirm our results and validate the murine model as a useful experimental system, we assayed PBMC-derived DC. As observed with BM-derived DC, mammalian MIF induced activation of DC in a stronger manner than did filarial homologues as seen by surface marker expression and cytokine production. 

The results summarised above show that direct stimulation of DC with any of the MIF homologues does not induce significant changes in the phenotype of these cells. Silent activation of DC has been previously described; BM-DC stimulated with SEA present an immature-like phenotype yet they induce strong Th2 responses confirming cell activation by the helminth product (Pearce et al., 2006). We therefore investigated whether filarial MIF influences DC-mediated T cell activation.  DC were treated overnight and transferred into mice, and antigen specific responses were analysed by re call assay. In this setting, MIF treated DC failed to stimulate MIF-specific immune responses. Subsequently, in analysing the effect of MIF on responses to a model antigen, DC were co-pulsed overnight with Bm-MIF-1, Bm-MIF-2 or mouse-MIF and OVA, and immune responses to OVA were measured.  Although Bm-MIF-2 induced higher OVA-specific proliferation and IL-10 production, this was not statistically significant. DC pulsed with OVA alone failed to induce OVA-specific responses and therefore comparison with MIF treated groups is inconclusive.
The inability of un-stimulated DC to induce OVA specific responses could be overcome using TCR-transgenic mice specific for OVA (DO11.10, OTII). Unfortunately at the time of these experiments these mice were not easily available. 
In vivo transfer experiments have only been performed once, thus making it difficult to draw any conclusions on the effect of MIF in DC mediated T cell responses. 













MIF effect on dendritic cell differentiation.
1	Introduction. 
During the course of infection different life stages of filarial parasites encounter a whole range of cells from the host immune system, from fully differentiated Langerhan cells (LC) in the skin (encountered by L3 at the infection site) to immature monocytes in the blood (Mf). Importantly, filarial parasites secrete ES products throughout their life cycle, and therefore have the opportunity to influence the differentiation and maturation state of host cell populations.

Macrophages and DCs differentiate from monocyte precursors through a finely controlled process strongly dependent on the cytokine milieu. For example, IL-6 and IFN-g can skew monocyte differentiation toward macrophages at the expense of DC maturation (Chomarat et al., 2000; Delneste et al., 2003), while on the other hand TNF-a favours DC differentiation (Chomarat et al., 2003).

Microbial components are also known to affect the process of macrophage and DC differentiation from monocytes. LPS has been shown to block DC differentiation from human monocytes (Palucka et al., 1999), and to arrest maturation of DC from murine bone marrow when present during the differentiation process (Lutz et al., 2000). Furthermore, several studies showed the ability of live parasites and parasite-derived products to influence DC differentiation. Human monocyte-derived DC in the presence of P. falciparum-infected erythrocytes (Urban et al., 1999) or B. malayi Mf (Semnani et al., 2003) have impaired capacity to stimulate T cells. Furthermore, ex vivo LC cultured in the presence of B. malayi L3 showed down-regulated expression of surface MHC-I and II, resulting in decreased ability of LC to promote CD4+ T cell proliferation (Semnani et al., 2004). In addition, filarial parasite-derived antigens have been shown to have an effect on DC maturation from both human blood and murine bone marrow. PBMC-derived DC differentiated in the presence of B. malayi Mf showed hyporesponsiveness to subsequent stimulation with Staphylococcus aureus (Semnani et al., 2001). Moreover, both DC and macrophages derived from bone marrow from mice exposed to A. viteae ES-62, failed to respond to LPS stimulation (Goodridge et al., 2004)

Previous chapters have documented the ability of Bm-MIF homologues to both mature macrophages and DC in different respects. This chapter set out studies of the interaction of both mammalian and filarial MIF homologues with APC during their differentiation from myeloid precursors in both in vitro and in vivo settings.
2	Results.
2.1	MIF treatment during DC differentiation impairs subsequent activation by LPS.
2.1.1	MIF homologues impair human DC activation by LPS. 	
In a related study, human monocyte-derived macrophages which were differentiated in the presence of GM-CSF and Plasmodium MIF show impaired responsiveness to LPS (K.D. Augustijn unpublished observations). For this reason, in parallel to the studies on human DC activation by MIF (chapter 4) the effect of MIF homologues on human DC differentiation was analysed. 
PBMC were purified as described in Materials and Methods, and cells were cultured with GM-CSF in the presence of increasing concentrations of recombinant MIF. After 7 days, 1 µg/ml of LPS was added and cells were cultured for a further 24 hours. Supernatants were harvested and cytokine production was measured by ELISA. Dendritic cells derived from monocytes grown for 7 days with GM-CSF responded to LPS by producing IL-12p40 and IL-6. However, cells from cultures containing MIF showed marked inhibition of cytokine production (Fig. 5.1).  Both filarial MIF homologues, and mouse-MIF inhibited IL-12p40 production in a dose dependent manner. In contrast, only mouse-MIF affected IL-6 production, and IL-6 induction by LPS remained unaffected by the presence of filarial MIF. As shown in chapter 4, MIF activates both human and murine derived DC equally, validating the use of bone marrow-derived DC in this study. To further analyse the effect of MIF during APC differentiation, BM derived murine cells were then investigated.

2.1.2	MIF homologues impair murine bone marrow-derived DC activation by LPS. 
Murine DCs were cultured as described before in the presence or absence of 10 µg of Bm-MIF-1, Bm-MIF-2 or mouse-MIF.  On day seven, 1 µg/ml of LPS was added to the media and cells were cultured for a further 24h.  After this period, DC activation was analysed by flow cytometry, and supernatants were harvested for cytokine ELISA. The level of cytokine released in response to LPS was found to be similar, irrespective of the differentiation conditions used to derive DC (Fig. 5.2a). However, 

DCs that had been differentiated in the presence of filarial MIF showed decreased up-regulation of MHC-II and co-stimulatory markers compared to DC in the presence of GM-CSF alone (Fig. 5.2b). Indeed, the presence of Bm-MIF-2 in DC cultures abolished their capacity to up-regulate MHC-II, CD80 and CD86 altogether. In contrast, cells that had been incubated in the presence of mouse-MIF maintained their ability to respond to LPS. Moreover, when analysing activation by LPS, we observed that cells from MIF-containing cultures showed lower levels of surface markers before LPS addition compare to GM-CSF alone (Fig. 5.2b solid lines). 

2.1.3	MIF homologues decrease percentage of CD11c+ cells.
Having observed these differences in surface marker expression, we analysed DC phenotype in further detail staining for the myeloid marker CD11b, and the dendritic cell marker CD11c. Under normal conditions of culture with GM-CSF, approximately 75% of bone marrow cells become CD11b+CD11c+ by day 7. However, the presence of MIF homologues in the culture media decreases this percentage. Cells differentiated in the presence of Bm-MIF-1, Bm-MIF-2, or mouse-MIF yield 61%, 49.8% and 67.7% CD11b+CD11c+ cells respectively (fig. 5.2c).












2.2	Bone marrow derived DC differentiation.
To further study the effect of MIF homologues on DC differentiation, a series of time course experiments with murine bone marrow were performed (Fig. 5.4). Bone marrow cells were obtained as described in Material and Methods and cultured with GM-CSF in the presence or absence of 10 µg of each of the recombinant MIF proteins previously treated with polymixin B. Polymixin B-treated PBS was used as buffer control. Cells were cultured in 24 well plates at 3.75x105 cells/ml (2 ml per well) in triplicate wells. On days 3 and 6, 1 ml of media was removed and replenished with fresh media containing GM-CSF in the presence or absence of MIF depending on the experiment (Table 5.1). At each time point cells were harvested to analyse cell phenotype by flow cytometry, and supernatants were stored for cytokine measurement by ELISA. 

The phenotype of differentiating bone marrow cells was studied using the following surface markers: the myeloid marker CD11b (Mac-1), the granulocyte marker GR1 (Ly-6G), the macrophage marker F4/80, and the dendritic cell marker CD11c. For flow cytometry analysis, cells were gated on the CD11b+ population as this remained unchanged irrespective of the culture conditions (Fig 5.5a). 











expression. CD11c expression increases with time, and by day 9 80-90% of the cells are CD11c+. Two populations can be distinguished within the CD11c+ cells, those that remain GR1+ and those that have become GR1–. Both CD11c+GR1+ and CD11c+GR1– remain CD11b+. These percentages may vary slightly between experiments, and depending on the source of GM-CSF, but by the end of the culture period, only 2-5% of the CD11b+ cells are CD11c-. This phenotype differs strikingly with the phenotype presented when cells are differentiated in the presence of MIF, particularly with Bm-MIF-2 where only 53% of the cells are CD11c+ by day 9 (Fig. 5.5c). Conversely, while only 9% GR1+CD11c– cells remain by day 6, and 1.4% by day 9 in GM-CSF cultures, this proportion remains at 49% (day 6) and 23% (day9) in the presence of Bm-MIF-2. 

2.2.1	Presence of MIF in the culture media does not affect total cell yield.




2.2.2	Bone marrow differentiation in the presence of filarial MIF yields lower numbers of CD11b+CD11c+ cells by maintaining CD11b+GR1+ cells. 
A closer analysis of the different populations generated during differentiation showed that while MIF does not affect total cell number or total CD11b+ cells (fig 5.6 a and b), many cells cultured in the presence of filarial MIF did not up-regulate CD11c expression (figure 5.5.c middle panels), but remained GR1+. This effect of MIF on DC differentiation was also found to be consistent in two mouse strains and using different culture conditions, see table 5.1. 
Three different experiments were performed in triplicate wells. In experiment i: BM-cells from C57BL/6 mice were cultured with X63 supernatant as a source of GM-CSF. Experiments ii and iii: BM-cells from BALB/c mice were cultured with rmGM-CSF. In experiments i and ii recombinant MIF protein was added at each time point with fresh media containing GM-CSF, cells in experiment iii only received recombinant MIF protein on the first day. 
Figures 5.7 and 5.8 compare percentages and absolute numbers of both CD11b+CD11c+ and CD11b+GR1+ during the time course for all three experiments.


















observed when calculating absolute numbers, as the number of total cells recovered did not differ between treatments. Absolute numbers of CD11b+CD11c+ DC were lower when cells had been differentiated in the presence of Bm-MIF-2, under conditions which yielded the highest CD11b+GR1+. Although Bm-MIF-1 slows CD11c+ expression, by day 9 CD11b+CD11c+ levels from cells incubated with either Bm-MIF-1 or mouse MIF were similar to control conditions. 

2.2.3	CD11b+CD11c+ DC generated in the presence of Bm-MIF-2 are MHC-II low.








The results described so far, suggest that Bm-MIF-2 impairs dendritic cell differentiation by maintaining a population of CD11b+GR1+ cells. A set of myeloid cells with a CD11b+GR1+ phenotype described in different disease situations, from parasite infections to cancer (Brys et al., 2005; Huang et al., 2006; Makarenkova et al., 2006), has been characterised by their suppressor capacity and play an important role in the down-modulation of immune responses in these situations. 
T cell hyporesponsiveness is one of the key features during filarial infection and it has been previously proposed that antigen-specific T cell hyporesponsiveness might be mediated by antigen presenting cells (Allen et al., 1996). Moreover, it is known that antigen presenting cells elicited during filarial infection have the ability to suppress T cell proliferation (Allen and MacDonald, 1998; MacDonald et al., 1999; Loke et al., 2000b). Furthermore, in chapter 3 we showed that Brugia MIF homologues in combination with IL-4 induce macrophages to adopt a suppressive phenotype. 
Thus, in addition to impairment of DC differentiation by Bm-MIF-2, this product may act on CD11b+GR1+ myeloid cells to promote suppressive activity. This might be a previously unrecognised mechanism by which filarial parasites induce down modulation of parasite specific immune responses. To test this hypothesis further studies were performed to analyse whether CD11b+GR1+ cells generated in the presence of Bm-MIF-2 function as myeloid suppressor cells.
2.2.4	MIF homologues enhance autologous T cell proliferation.
To assess the function of CD11b+GR1+ cells from Bm-MIF-2 cultures, 2 x105 day 9 BM-derived cells were cultured with CD4+ purified T cells in the presence of 1 µg/ml of Con-A. Cells were co-cultured for 72 h and proliferation was measured by 

thymidine incorporation.  T cells co-cultured in the presence of myeloid derived cells proliferated to a greater extent than T cells alone did (Fig. 5.10). Interestingly, cells that had been cultured in the presence of MIF homologues enhanced T cell proliferation further than cells differentiated with GM-CSF alone. Furthermore, cells differentiated with GM-CSF in the presence of Bm-MIF-2 induced the highest proliferation despite half of them having a CD11b+GR1+ myeloid phenotype. 
Further experiments and analysis are needed to draw a firm conclusion on the effect on T cell proliferation by MIF treated APC. The results from this single experiment suggest that the CD11b+GR1+ cells generated by Bm-MIF-2 are not myeloid suppressor cells as hypothesised. 

2.2.5	Bm-MIF-2 induces IL-6 production from bone marrow cells during DC differentiation. 







2.2.6	F4/80 expression during DC differentiation.
It has been previously described that IL-6 skews monocyte differentiation from DC to macrophages (Chomarat et al., 2000). Thus, to determine whether lower DC yields under Bm-MIF-2 conditions were due to a preference for macrophage differentiation induced by IL-6, F4/80 expression during differentiation was measured. 
Under each culture condition studied, F4/80 was expressed at variable levels throughout the differentiation period; as with GR1 expression, surface F4/80 decreased as DC matured.  By the end of the differentiation process, F4/80+ cell numbers varied between culture conditions, however no statistically significant change was observed (Fig. 5.12). Furthermore, F4/80 positive cells generated in the presence of recombinant MIF are CD11c+. F4/80 is a marker of both macrophages and immature DC, so that slightly higher levels of F4/80 in Bm-MIF-2-containing cultures can be explained by the presence of less mature DC (as seen by lower surface MHC-II expression) rather than the development of a macrophage-like phenotype. 

2.2.7	Bm-MIF-2 impairs DC differentiation in an IL-6 independent manner.




BM cells from BALB/c WT and IL-6 –/– mice were cultured as described, in triplicate wells in 24 well plates. X63 supernatant was used as a source of GM-CSF, and recombinant protein was added only at the start of the culture period. DC phenotype was analysed on days 3, 6 and 9 by flow cytometry staining. As in previous experiments no differences in total cell numbers or total CD11b+ cells were observed. By day 3 all three MIF homologues delayed DC differentiation (Fig. 5.13), and by day 9 only cells cultured in the presence of Bm-MIF-2 yielded lower CD11b+CD11c+ numbers.  Crucially, there were no significant differences between wild type and IL-6 deficient mice throughout the experimental period.
As expected, Bm-MIF-2 induced IL-6 production by WT cells but not from the IL-6 –/– group (not shown), suggesting that while IL-6 production is induced by Bm-MIF-2, this cytokine is not required to alter DC differentiation in the manner observed.












2.3	B. malayi adult worms but not microfilariae impair DC differentiation in vitro.
To extend the analysis of the effect of B. malayi on DC differentiation from myeloid precursors, BM cells were differentiated in the presence of live worms using a transwell system. BM cells from C57BL/6 mice were placed in the lower chamber, and 4-6 adult worms or 5,000 microfilariae in the upper chamber, control wells contained GM-CSF-media in the upper chamber. Media was replenished on days 3 and 6 and DC phenotype was analysed by flow cytometry on day 9. 
Figure 5.14a shows representative plots of day 9 cells gated on the CD11b+ population (>95%). Although the effect is not as profound as that observed with recombinant protein, in the presence of adult worms the percentage of CD11b+CD11c+ cells was lower, with a corresponding increase in the CD11b+GR1+ population. This observation was specific of adult worms, as cells cultured in the presence of B. malayi Mf yield equivalent proportions to cells grown with GM-CSF alone (Fig.5.14b). Whether Mf exert other effects on DC differentiation, not apparent in this specific system, needs to be determined in further studies.






2.4	Bone marrow derived macrophage differentiation.
Because of the dramatic effects of MIF homologues on DC differentiation from bone marrow, similar experiments were performed on the macrophage lineage. BM-macrophages were therefore generated in the presence or absence of MIF recombinant protein. In a preliminary experiment, we observed that addition of MIF enhanced cell expansion, resulting in higher cell recovery by day 6. Further analysis showed that the additional cells were not macrophages, as the total number of macrophages did not change in the presence of MIF, although the percentage of macrophages declined within a larger overall total. 
To further analyse the effect of MIF in cultures of differentiating macrophages, cells were cultured for up to 12 days. In a parallel experiment, BM cells were cultured in media without differentiation factor, in the presence or absence of MIF. 
In the presence of M-CSF bone marrow cells expand up to day 6 when cell numbers start decreasing (Fig. 5.15a, black line). In contrast, in the absence of differentiation stimulus bone marrow cell survival is greatly impaired and cell recovery is 10 fold reduced from that in the presence of M-CSF (Fig. 5.15c, black line). However, in both situations MIF homologues enhanced cell survival. This was particularly noticeable by day 9, when there is a dramatic drop in cell recovery from either cultures with M-CSF alone, or total absence of differentiation factor. In the absence of differentiation factor cells failed to expand, and the few cells that remain in the culture differentiate into macrophages, most probably induced by adherence (Fig. 5.15d). 








of M-CSF, MIF reduces macrophage differentiation (Fig. 5.16a), although absolute numbers are higher probably due to a higher rate of cell proliferation.  On the contrary, cells that have not received differentiation stimuli other than MIF protein differentiate into macrophages to similar percentages than cells with M-CSF alone (Fig. 5.16b). In addition, macrophages differentiated in the presence of MIF homologues did not respond to LPS (Fig. 5.16c), suggesting that MIF homologues impair macrophage maturation from myeloid precursors. Cultured cells without differentiation factor did not yield enough cells to analyse activation by LPS. 

2.5	B. malayi effect on BM cell differentiation ex-vivo.
Several studies have demonstrated the effect of Brugia derived antigens and different live parasite stages on DC differentiation from monocytes in vitro (Semnani et al., 2001; Semnani et al., 2003; Semnani et al., 2004). However, in the human setting, the direct effect of the parasite on DC differentiation in vivo is difficult to assess. B. malayi does not complete a full infection cycle in mice, and in order to study immune responses to the adult stages it is necessary to surgically implant B. malayi adult parasites in the peritoneal cavity of mice. Adult worms can survive in this compartment for some weeks and induce strong type 2 responses (Lawrence et al., 1994). 
Studies with excretory-secretory products of a related filarial parasite (A. viteae) have shown a strong effect on both mature and immature DCs (Whelan et al., 2000; Goodridge et al., 2004).  Goodridge et. al. devised a system using an osmotic pump to expose mice to physiological levels of ES-62 for 2 weeks. Ex-vivo BM-derived DC or macrophages from ES-62 exposed mice failed to respond to LPS stimulation. In this study no defect on APC differentiation was observed aside from hyporesponsiveness to LPS. 
Both Bm-MIF-1 and -2 are mainly secreted by the adult parasite and we have observed that mice implanted with adult worms generate Bm-MIF specific antibodies (Fig. 5.17). Furthermore, we have shown that in vitro, adult worms impair DC differentiation (Fig. 5.14). To assess how filarial infection affects bone marrow differentiation ex-vivo, we used the implant model as a system to deliver B. malayi ES in vivo.
C57BL/6 mice were implanted with 5 adult B. malayi worms in the peritoneal cavity for 3 weeks and every week bone marrow was collected and cultured in the presence of GM-CSF for DC or M-CSF for macrophage differentiation. Cultures were followed for 9 days for DC and 6 days for macrophages, following which cells were stimulated with LPS overnight and activation state analysed by flow cytometry and ELISA (Fig. 5.18). 

2.5.1	Brugia malayi implantation in vivo does not affect bone marrow differentiation ex-vivo.











 and infected mice, after weeks 1, 2 and 3 (one mouse per group is shown). Despite variability in the cultures between days, no differences were observed in DC or macrophage differentiation from precursors from naïve or B. malayi infected mice.

2.5.2	Ex-vivo BM-derived DC from B. malayi infected mice respond normally to LPS.
On day 6 and 9 BM-derived macrophages and DC respectively, were incubated with LPS overnight. DC activation was analysed by flow cytometry, which showed that both DC from naïve and implanted mice up-regulate surface markers following LPS stimulation. Figure 5.20 shows representative histograms for CD40 up-regulation by LPS. In the same experiments, MHC-II, CD80 and CD86 were also up-regulated (data not shown). Supernatants from both macrophages and DC treated with LPS were also harvested for cytokine analysis by ELISA. Figure 5.21 shows IL-10 production by LPS-stimulated macrophages (left) and DC (right) from naïve and infected mice. No differences were observed in cytokine levels from different cell precursors. In addition, no differences in IL-6 and IL-12 production were apparent after LPS stimulation by cells from naïve or implanted mice (data not shown).  
















Semnani et al. have previously shown that B. malayi has a direct effect on DC differentiation in vitro. Additionally, Brugia is known to strongly induce suppressive antigen presenting cells in vivo (Allen et al., 1996; MacDonald et al., 1999). However the effect of Bm-MIF homologues during the differentiation of distinct APC populations from myeloid precursors has not been previously studied.
 
In preliminary experiments we saw that DC differentiated in the presence of MIF homologues had impaired responses to LPS. Phenotype analysis revealed that in the presence of MIF homologues, cells failed to differentiate into CD11c+ DC but rather remained within a population of cells characterised by CD11b and GR1 co-expression. While this population was absent under normal DC-differentiation conditions, it was particularly increased when Bm-MIF-2, but not -1 or mouse-MIF, was added to the culture media.
Recent reports have characterised CD11b+GR1+ myeloid cells for its suppressor capacity. These myeloid suppressor cells express CD115 and F4/80 (Huang et al., 2006) and suppression has been shown to be mediated by arginase production (Bronte et al., 2003; Bronte and Zanovello, 2005). Experiments were therefore performed to assess whether CD11b+GR1+ cells generated in the presence of Bm-MIF-2 are indeed myeloid suppressor cells, as this would contribute to the hyporesponsiveness seen during filarial infection. 
Under our experimental conditions 20-30% BM cells cultured with GM-CSF in the presence of Bm-MIF-2 are CD11b+GR1+ by the end of the cultured period, compared to 2-5% with GM-CSF alone. These CD11b+GR1+ cells showed low levels of F4/80 and CD115 (not shown). When analysing the functional capacity of these cells, however, BM-cells that had been cultured in the presence of MIF homologues, not only failed to suppress T cell proliferation but rather enhanced it. Furthermore, we failed to detect any arginase-1 expression by real time PCR on BM-cells differentiated with GM-CSF with or without MIF homologues (data not shown).
Taken together these data show that BM-cells cultured with GM-CSF in the presence of Bm-MIF-2 failed to differentiate into mature DC, and maintain a myeloid undifferentiated state characterised by expression of CD11b and GR1, rather than becoming myeloid suppressor cells. The idea that Bm-MIF-2 impairs DC differentiation is further supported by the observation that the CD11b+CD11c+ population generated in the presence of Bm-MIF-2 is MHC-II low and F4/80 positive, which is characteristic of immature DC, suggesting that Bm-MIF-2 inhibits both DC differentiation and maturation processes.

The impairment of DC differentiation mediated by Bm-MIF-2 was accompanied by IL-6 production throughout the culture period. Because IL-6 drives macrophage differentiation from monocytes, we analysed whether Bm-MIF-2 treatment skews differentiation toward macrophage phenotype. Bm-MIF-2 effect on IL-6 deficient BM-cells was analysed. Bm-MIF-2 inhibited DC differentiation from BM-cells from IL-6 –/– mice to the same extent as in wild type cells. Moreover, Bm-MIF-2 did not enhance F4/80 or CSF-1R expression on BM-cells, two markers of IL-6 driven macrophage differentiation (Chomarat et al., 2000).

One explanation for Bm-MIF-2 to impair DC differentiation and maintain an undifferentiated myeloid state might be that in vivo other stimuli will drive these CD11b+GR1+ towards a macrophage-like phenotype, as CD11b+GR1+ cells comprise a mix of different myeloid cells at different stages of differentiation including granulocytes, monocytes and immature myelomonocytic cells with the ability to differentiate under the appropriate stimuli (Bronte et al., 2003).  In our DC-differentiation experiments GM-CSF was always present in the media. Transfer of cells to M-CSF-containing media would determine whether CD11b+GR1+ cells cultured in the presence of Bm-MIF-2 maintain the ability to differentiate into macrophages or rather Bm-MIF-2 has completely inhibited differentiation.  

To further study the effect of B. malayi in DC differentiation, BM-cells were cultured with GM-CSF in the presence of live parasites. A transwell system was used to allow the ES secreted by the parasite to interact with the cells without disturbance due to worm mobility. Adult B. malayi worms but not microfilariae impaired DC differentiation over a 9 days culture period. Although adult worms secrete higher MIF levels than Mf (Zang et al., 2002), we cannot conclude the effect observed is solely due to MIF secretion, neither can we confirm the effect is adult specific. First, parasites secrete a complex mix of proteins in ES of which MIF is only a small fraction. Moreover, anti-MIF antibody treatment did not inhibit the effect; however antibody titration and confirmation of its blocking ability are needed to be able to draw further conclusions. Second, the number of Mf used in this experiment might be too low to observe any effects on DC differentiation. In experiments by Semnani et. al., up to 50,000 Mf were used, which was 10 fold higher than the number used in this experiment. Further experiments with different numbers of Mf should be performed to assess whether DC differentiation impairment is an adult specific effect.

To further elucidate the effect of MIF homologues on myeloid differentiation, macrophage differentiation from BM-precursors was studied.  BM-cells were cultured with M-CSF in the absence or presence of MIF homologues. In parallel, direct effect of MIF in BM differentiation was assayed in cultures without differentiation factor.  In both these situations it was observed that addition of both host and parasite derived MIF homologues increased cell yield.  Interestingly, either MIF homologue in the presence of M-CSF reduced the macrophage percentage by the end of the culture period in a similar way to the impairment observed during DC differentiation by Bm-MIF-2. However, the absolute number of macrophages was comparable between treatments, as increased numbers of cells in the presence of MIF compensated for the lower percentage. 
On the other hand, cells that have been cultured in the presence of MIF alone reached macrophage percentages similar to those obtained in parallel cultures with M-CSF, although cell yields were 10 fold lower. In the absence of any other stimuli the most probable differentiation stimuli is adherence; there is a small percentage of cells that differentiate to macrophages in complete absence of stimuli. MIF homologues in this situation might just be providing a survival and proliferation mechanism rather than differentiation stimuli. It has been previously described that MIF induces proliferation and inhibits apoptosis in fibroblasts via activation of MAPK pathways (Leng et al., 2003). Although we have not analysed this pathway in these experiments, in chapter 3 we showed both filarial and mammalian MIF ability to induce ERK1/2 phosphorylation, further studies are required to assess whether this MIF feature might be playing an important role in these experiments. CSFE and Annexin V staining, and analysis of MAPK will help elucidate these questions.
Taken together the above observations show that Bm-MIF-2 in the presence of GM-CSF, and either MIF homologue in the presence of M-CSF impair differentiation to the corresponding mature APC (DC, or macrophage respectively). Furthermore, APC matured in the presence of MIF homologues have an impaired capacity to be activated by LPS stimuli, suggesting a hyporesponsive state. Immune hyporesponsiveness is an important feature during filarial infection, and it has been related with impair monocyte function (Sasisekhar et al., 2005).  Our results suggest filarial MIF might be playing an important role in the induction of hyporesponsive state. 

Finally, the effect of in vivo B. malayi infection on APC differentiation was analysed. W. Harnett’s group has previously described the ability of filarial derived products treatment in vivo to impair DC and macrophage reactivity ex-vivo (Goodridge et al., 2004).  Mice were implanted with 5 B. malayi adult worms in the peritoneal cavity, and in vitro BM differentiation was analysed on weeks 1, 2 and 3 post-implant. Both BM cells from naïve and implanted mice differentiated normally to DC and macrophages. Furthermore, DC and macrophages derived form either naïve or infected mice responded to LPS stimuli by up-regulating activation markers and inducing cytokine production to equivalent levels. These data suggest that B. malayi in the peritoneal cavity has no effect on myeloid differentiation in the bone marrow. 




























The role of host MIF during B. malayi infection.
1	Introduction.
In order to study immune responses to Brugia malayi, a robust and consistent mouse model has been established. Surgical implantation of adult worms into the peritoneal cavity of mice permits parasite establishment and survival for many weeks. Parasite implantation results in the recruitment of a host cell population consisting mainly of eosinophils and macrophages (MacDonald et al., 2003), with an overall antigen-specific type 2 responses (Lawrence et al., 1994). These nematode elicited macrophages have a specific phenotype characterised by expression of alternative activation markers Ym-1, Fizz-1 and Arginase-1 and the ability to suppress T cell proliferation (Loke et al., 2000b) (Loke et al., 2000b).  

In other infection systems, the importance of host MIF has been described. For example, MIF-deficient mice are more susceptible to both protozoa (L .major, T. cruzi) and helminth parasites (T. crassiceps) (Jüttner et al., 1998; Rodríguez-Sosa et al., 2003; Reyes et al., 2006). Moreover, treatment with MIF-blocking antibodies increases worm burdens in Schistosoma-infected mice (Stavitsky et al., 2003). In contrast, however, P. chabaudi infection of MIF-deficient mice results in less severe anemia and increased survival (McDevitt et al., 2006).





Five female mice per group were surgically implanted with 5 adult worms for 3 weeks.  Two types of control groups were used.  Surgically implanted C57BL/6 and 129 mice were used as wild-type control. Intraperitoneal administration of a 4 % thioglycollate solution was used to recruit non-alternative activated macrophages. 





Staining of the peritoneal exudate cells with antibodies against F4/80 and Siglec F distinguishes 3 populations. Eosinophils are characterised by high expression of Siglec F and low levels of F4/80, while macrophages present high levels of F4/80 and are Siglec F negative (Fig 6.2a). A third population of Siglec F negative - F4/80 low cells were considered neutrophils. Differential cell counts were also performed by counting 300 cells on cytospun slides stained with Diff Quick, confirming the cell populations analysed by FACS (Fig. 6.2b).




Brugia malayi adult antigen-specific antibody responses in implanted mice were measured by ELISA. Although all three groups mounted antibody responses after 3 weeks, total antibody levels were lower in MIF deficient mice (Fig. 6.4).  Analysis of antibody isotypes suggested once more that differences can be attribute to the background mouse strain. 129 mice showed the highest levels of both IgG1 and IgG2a (Fig.6.5), while no differences between C57BL/6 and MIF deficient mice were observed for these isotypes. Furthermore, although MIF-deficient mice showed lower levels of IgG2b and IgG3, differences amongst the 3 genotypes were marginal.
 
2.3	Antigen specific responses in the spleen.







deficient mice; however this did not prove reproducible, as in experiment 3 IL-5 production was equivalent in both 129 and MIF-/- mice, and higher than C57BL/6. 
Similar results were observed for IL-10. 129 mice induced the highest IL-10 levels in experiment 2, however both 129 and MIF deficient mice presented similar IL-10 levels in experiment 3, and these were higher than IL-10 induced by C57BL/6 mice.
These observations suggest once again that differences might be due to strain and not gene deficiency, and we can not conclude from these data whether MIF has an important role in driving type 2 responses during Brugia infection.
On the other hand, when analysing type 1 cytokines, some differences were observed between WT and MIF-deficient mice. Experiment 2 showed significant levels of IFN-g produced only by MIF deficient mice. No differences were observed between groups in experiment 3, and IFN-g production was much lower than in experiment 2, however the MIF –/– group was the only in which significant antigen-specific IFN-g production (compared to cells cultured in media alone) was observed. The same was true for TNF-a in the first experiment, as MIF –/– mice were the only group to induce antigen specific TNF-a production.  Although not conclusive these observations suggest that a higher inflammatory response is mounted in the absence of MIF. 
2.4	Peritoneal macrophages activation state. 








cDNA was prepared. Ym-1, Fizz-1, Arginase-1 and iNOS mRNA levels were measured by real time PCR using GRI-Chromo4.  (Fig. 6.7-8)
Despite observing differences between experiments, macrophages obtained from mice harbouring Brugia malayi adults expressed high levels of Ym-1, Fizz-1 and Arginase-1 compare to thioglycollate-elicited control macrophages in all three experimental groups. Furthermore, no differences were observed in the overall macrophage activation state, as the Arginase-1:iNOS ratio was similar for all three implanted groups, showing a predominant type 2 phenotype.
Experiment 2 suggested that MIF –/– mice develop lower levels of Ym-1, Fizz-1 and Arginase-1 in response to B. malayi implantation.  This observation agrees with lower levels of IL-5 in experiment 2 (Fig. 6.5a), and lower levels of arginase activity (see below, Fig. 6.9a) suggesting that type 2 responses depend on endogenous MIF.  However, this was not repeated in experiment 3 where Ym-1, Fizz-1, Arginase-1, IL-5 and arginase activity were equivalent in 129 and MIF deficient mice. 

2.5	Peritoneal macrophage functional assays.










To assay the capacity of macrophages to suppress proliferation, adherent macrophages were co-cultured with EL-4 cells for 72 h and proliferation was measured by thymidine incorporation. Macrophages recovered from all three implanted groups of mice completely suppressed EL-4 proliferation, compared to EL-4 alone or EL-4 co-cultured with thioglycollate-elicited macrophages (Fig. 6.9b). No difference was observed in the suppressor activity between experimental groups.   

2.6	The responses to Brugia malayi implantation of MIF-deficient mice on BALB/c background.
Following the experiments described above, MIF –/– mice on the BALB/c background became available. WT and MIF-deficient BALB/c mice were surgically implanted with 5-6 B. malayi adult worms, and naïve mice were used as controls. PEC differential cell counts, splenic recall responses, and peritoneal macrophage activation were all analysed.
2.6.1	Peritoneal cell recruitment.





2.6.2	Antigen specific recall responses in the spleen.
Spleens were collected and antigen specific responses were measured by recall analysis. Splenocytes from naïve and infected mice were cultured for 72 h in the presence of media, 1 µg/ml of Con A or 10 µg/ml of B. malayi adult antigen. Supernatants were harvested for cytokine ELISA and proliferation measured by thymidine incorporation. Surprisingly, MIF deficient mice induced higher type 2 responses than implanted WT mice as seen by significantly higher levels of IL-4, IL-5, IL-10 and IL-13 (Fig. 6.11a).  On the other hand, pro-inflammatory cytokine production (IFN-g and TNF-a) was not significant in any of the implanted groups when comparing to naïve mice. 
2.6.3	Peritoneal macrophage activation state.
PEC were allowed to adhere overnight and macrophages were harvested in TRIzol for RNA extraction. Ym-1, Fizz-1, Arginase-1 and iNOS levels were measured by real-time PCR using GRI-Chromo4. 
None of the genes analysed could be amplified from RNA from naïve WT macrophages, and only one mouse out of 5 MIF deficient naïve showed some expression. This suggests that either the RNA or first strand cDNA quality was not good enough for quantitative PCR as no b-actin or GAPDH were detected over background levels.  However all genes analysed could be amplified from samples from implanted mice and both WT and MIF deficient mice showed equivalent levels of b-actin and GAPDH (Fig.6.12a). One explanation for this is that resident macrophages from naïve mice are in a completely non-activated state and might therefore contain less RNA as their transcriptional activity might be lower. Analysis of the RNA by electrophoresis shows this to be the case in MIF deficient mice. 1 µl 

of RNA from implanted mice contained higher RNA levels than the equivalent volume from naïve MIF deficient mice, however, both naïve and implanted WT mice yielded equivalent amounts of RNA suggesting that some problem occurred in the transcription reaction (Fig.6.12b). A second RT reaction was performed from the same RNA samples with equivalent results (no GAPDH or b-actin amplification, Fig. 6.12a), and for this reason naïve controls were removed from the study and comparisons solely made between WT and MIF deficient implanted mice.
In the BALB/c background, B. malayi implantation induced higher Ym-1 and Fizz-1 expression in MIF deficient mice than in the WT group (Fig 6.13a). Arginase-1 levels were also higher in MIF deficient mice, however MIF deficient mice were the only group to express some iNOS, and the Arginase-1:iNOS ratio suggested WT macrophages are more type 2 at least regarding their metabolic state (Fig. 6.13b). Interestingly, MIF deficient macrophages from infected mice also had higher suppressor capacity than macrophages from BALB/c WT implanted mice (Fig 6.14).
Taken together, the evidence for higher Ym-1, Fizz-1 and Arginase-1 expression, and the stronger suppressor capacity of MIF-deficient macrophages from implanted mice suggest that the lack of host MIF enhances alternative activation.  These observations are consistent with the splenic recall data as higher Th-2 responses were evident, particularly of IL-4 and IL-13 which can in turn induce higher alternative activation.























Several studies have described the importance of endogenous MIF in different infection settings. From bacteria to parasites, host MIF plays a role in resistance to infection as both MIF gene deficiency and antibody depletion increased parasite burdens. In addition, in vitro treatment with recombinant MIF reduces bacterial growth in human macrophages (Oddo et al., 2005), and in vivo treatment renders mice more resistant to infection (Pollak et al., 2005). 
MIF deficient mice are more susceptible to intracellular parasites, L. major and T. cruzi as seen by higher parasitemia (Satoskar et al., 2001; Reyes et al., 2006). Interestingly, in these studies no significant differences were observed in the adaptive immune responses as T cells from both WT and deficient mice proliferated similarly and produced comparable levels of type 1 and 2 cytokines. In contrast, increased susceptibility was due to the decrease of macrophage microbicidal activity in MIF deficient mice.  
MIF has also been shown to play a critical role in protection during helminth infection. MIF deficient mice are more susceptible to T. crassiceps (Rodríguez-Sosa et al., 2003), and S. japonicum infected mice treated with antibodies to MIF presented higher parasite burdens (Stavitsky et al., 2003).  During helminth infection, MIF deficient mice presented higher IFN-g and IL-13 levels than WT although IL-4 was not affected.  These observations agree with results from experiment 2 in which only MIF deficient mice induced antigen-specific IFN-g but no differences were observed in IL-4 production. However, although MIF deficient mice were the only group to induce antigen specific IFN-g in experiment 3, this was not significantly different to the control groups.  Furthermore, in experiment 3 MIF deficient mice induced higher IL-5 and IL-10 than C57BL/6 mice although these levels were equivalent to WT 129. Moreover, in BALB/c background MIF deficient mice induced higher type-2 cytokines than the WT group, with no differences observed in pro-inflammatory cytokine production.

A particularly interesting question is the role of MIF in eosinophil and macrophage recruitment and function, as this is an important feature during filarial infection. Endogenous MIF has been reported to be essential for eosinophil recruitment in OVA-induced airway inflammation, although MIF deficient mice presented normal eosinophil migration in the steady state (Mizue et al., 2005; Wang et al., 2006; Magalhaes et al., 2007). Furthermore, analysis of allergic responses in MIF deficient mice disagree as to the importance of endogenous MIF in mounting Th2 responses during allergic inflammation, Mizue et. al. showed reduced levels of IL-4, IL-5, IL-13 in MIF-deficient mice, but Magalhaes et. al. found no differences in antigen-specific responses between MIF –/– and WT. This discrepancy might be due to differences in the experimental settings, as both groups observed decreased IL-5 and IL-13 in the bronchoalveolar lavage fluid of MIF deficient mice compared to wild type.
In our experimental system, MIF-deficient mice showed lower eosinophilia than 129 mice in 3 experiments (table 6.2).  However no significant difference was observed with C57BL/6, and no differences were observed in eosinophil recruitment between WT and MIF deficient mice on the BALB/c background. From these observations we can conclude that in the first set of experiments differences between MIF deficient mice and 129 were due to strain background, and in our experimental setting endogenous MIF does not play an important role in eosinophil recruitment induced by B. malayi implant.
Our data do not accord with published studies on allergic inflammation; in addition to not having observed differences in eosinophilia between WT and MIF deficient mice, in BALB/c background B. malayi implant induced higher Th-2 cytokine production in MIF deficient mice, in contrast with the lower eosinophilia and lower Th-2 cytokine levels observed after OVA immunization and challenge in MIF deficient mice. From the observations reported here, no conclusion can be drawn on the role of MIF in driving Th-2 responses in the B. malayi implant model.



























Filarial infection is a major health problem in tropical countries. Infections are chronic and parasites can persist in the host for many years (Maizels et al., 1993). Recent research has demonstrated that this is due to the filarial nematodes’ ability to modulate the host immune system in a way that tolerates the parasites for long periods (Hoerauf et al., 2005). 

Immunosuppression in filarial infections has conventionally been measured by depressed antigen-specific T cell reactivity and there is now growing evidence that T regulatory cells play a major part in down-regulating immune responses (Taylor et al., 2005), however antigen presenting cells also play an important role in the control of immune responses to filarial infection (Hoerauf et al., 2005).  For example, one of the pathways for the induction and maintenance of regulatory responses is mediated by DC that are not fully functional. Both filarial antigen, and live parasites induce a hyporesponsive state on mature DC (Semnani et al., 2003; Semnani et al., 2004).
Arguably, the most important APC population in filarial infections is the macrophage, which sustains an anti-inflammatory phenotype (MacDonald et al., 1999; Loke et al., 2000b; Taylor et al., 2006). Thus, in an in vivo model of B. malayi macrophages recruited to the peritoneal cavity present an alternative activated phenotype characterised by the production of TGF-b, arginase-1 and reduced pro-inflammatory cytokines. Moreover, at the functional level, these nematode-elicited macrophages have been shown to be highly suppressive (MacDonald et al., 1999; Loke et al., 2000b). Furthermore, filarial antigens induce IL-10 production by macrophages (Osborne and Devaney, 1998; Brattig et al., 2004).

The long-term survival of helminth parasites, and their ability to down-modulate immune responses suggests that immune evasion depends on sophisticated mechanisms beyond the sole prevention of immunological attack. It is now known that filarial nematodes express and secrete a number of proteins that play a role in immune evasion. Within these ES products two homologues of the mammalian cytokine macrophage migration inhibitory factor (MIF) have been characterised in Brugia malayi (Bm-MIF-1 and -2) and other filarial nematodes (Pastrana et al., 1998; Zang et al., 2002). MIF homologues have now been found in many other parasitic helminths and thus, its role may be of general importance in the immunology of helminth infection (Tan et al., 2001; Wu et al., 2003).

Like mammalian MIF, B. malayi MIF acts as a macrophage chemoattractant, but also inhibits random migration of macrophages (Pastrana et al., 1998). Furthermore, Bm-MIF-1 has previously been linked to the recruitment of macrophages and eosinophils in a manner that resembles that of the live adult worm (Falcone et al., 2001).  However, whereas mammalian MIF is known to have pro-inflammatory properties (Lue et al., 2002), B. malayi induces strong anti-inflammatory reaction. Understanding the interaction of filarial MIF homologues with their mammalian counterpart, and the effect of these cytokines on antigen presenting cells during filarial infection will help elucidate the mechanisms by which filarial parasites down-modulate immune responses in the host.

1	Macrophage activation by MIF homologues depends on the cytokine environment.
Macrophages are one of the key effector cells during the infection and inflammation process. Present in every tissue of the body, macrophages represent a heterogeneous sub-population with distinct biological roles, Langerhans cells in the skin; osteoclasts in the bone; alveolar macrophages in the lung; Kupffer cells in the liver; microglia in the nervous system; splenic macrophages in the spleen; and circulating blood monocytes are some examples (Gordon and Taylor, 2005). As with other cells of the immune system this heterogeneity is crucially dependent on the cytokine microenvironment. Our view of macrophage function has been strongly influenced by the paradigm of activation of macrophages by type-1 IFN-gas is required for intracellular pathogen clearance (Kaufmann, 1993). The role of macrophages in type-2 situations was initially less apparent, however the presence of large number of macrophages at the site of helminth infection implies an important role for this cell type. Several studies have now shown the importance of type 2 activated macrophages during helminth infection (Hesse et al., 2001; Raes et al., 2005; Anthony et al., 2006).

From these more recent studies, it is now well established that helminth infection induces alternative activation of macrophages, dependent on the Th-2 cytokines IL-4 and IL-13. Such macrophages are characterised by their suppressor capacity, high expression of Ym-1 and Fizz-1, and skewing of L-arginine metabolism to the production or L-ornithine and urea due to the up-regulation of Arginase-1.  
An important set of studies which has contributed to this understanding is the mouse model of surgical implantation of adult B. malayi worms in the peritoneal cavity of mice. Infection recruits a cell population that is rich in macrophages and eosinophils, with macrophages characterised by a unique suppressive phenotype, with >13% of their mRNA devoted to express Ym-1, Fizz-1 and Arginase-1 (Loke et al., 2002).  Importantly, this parasite induced-cell recruitment to the peritoneal cavity and induction of alternative activation marker expression can be mimicked in vivo by repeated injection of Bm-MIF ((Falcone et al., 2001) and Gregory et. al. unpublished observations).

I have shown in chapter 3 that in vitro, both Bm-MIF-1 and -2 are capable of activating macrophages, in a manner dependent on the cytokine milieu and not entirely the same as macrophage activation by mouse-MIF.  Mouse-MIF induced TNF-a and IL-6 production from macrophages, whereas Bm-MIF-1 and -2 only induced low levels of these cytokines. However, Bm-MIF-1 and -2 induced high levels of IL-10, to a greater extent than mouse-MIF, suggesting that parasite MIF homologues might favour anti-inflammatory type-2 cytokine production. This observation was supported by the findings with IL-4 and MIF co-treatment of macrophages: IL-4 decreased IL-6 and IL-12 production induced by MIF, without changing the levels of IL-10.
IL-4 induces alternative activation of macrophages, which is strongly dependent on IL-4 mediated signalling (Linehan et al., 2003). In my experimental setting, MIF homologues failed to directly induce macrophage alternative activation, however, all three MIF homologues synergised with IL-4 by strongly enhancing Ym-1, Fizz-1, Arginase-1 and Mannose Receptor expression after 24 h of combined treatment. Most importantly, MIF was required in conjunction with IL-4 to render macrophages suppressive.  Finally, I show that MIF alone induces up-regulation of IL-4Ra and that MIF-induced IL-4Ra expression is further enhanced by IL-4. 
Despite not inducing alternative activation per se, MIF might be contributing to alternative activation by up-regulating IL-4Rathereby increasing IL-4 responsiveness. Moreover, MIF induces IL-6 in the absence of other stimuli, and this IL-6 production might contribute to the induction of Th-2 responses needed for the alternative activation of macrophages (Rincon et al., 1997; Porthouse et al., 2006).
Taken together, these observations suggest that although alternative activation induced by B. malayi cannot be accounted by MIF secretion alone, in the in vivo situation where strong type 2 responses are being induced by the worm and high levels of IL-4 are secreted, MIF might play an important role in amplifying type 2 responses by first recruiting macrophages to the site of infection followed by enhancement of macrophage responsiveness to IL-4 by increasing IL-4Ra in these cells.
2	Filarial MIF homologues do not activate mature DC but interfere with DC differentiation from myeloid precursors.
Dendritic cells are the major antigen presenting population of the immune system, with the ability to initiate antigen-specific responses by activating T cells, and to determine the final type of immune response through co-stimulatory signals. Bacterial and protozoal stimuli through TLR signalling induce DC to up-regulate MHC-II and the co-stimulatory molecules CD40 and CD80/86. These activated DC release pro-inflammatory cytokines, particularly IL-12, which in turn induce INF-g production by T cells. On the other hand, DC stimulated with helminth products do not show great phenotypic change but are able to drive Th-2 responses (Sher et al., 2003). 
Despite MIF homologues strongly influencing macrophage activation, they have little effect on DC. In chapter 4 I have studied the effects of both parasite and host MIF proteins on murine BM-derived and human PBMC-derived DC. Although both mouse and human MIF homologues activate DC by inducing class II molecules, co-stimulatory surface marker up-regulation, and cytokine production, neither Brugia MIF homologue altered DC phenotype significantly. Bm-MIF-2 but not Bm-MIF-1 induced some cytokine production by DC, but it did not reach activation levels induced by either mammalian protein. Most importantly, neither MIF homologue interferes with subsequent DC activation by LPS or mouse-MIF stimuli, suggesting Bm-MIF are not interacting with either the TLR or mouse-MIF signalling pathways. Moreover, when transferred in vivo, MIF-primed DC failed to elicit an immune response, and MIF did not interfere with immune responses to a model antigen. These in vivo experiments need repeating, and perhaps with the use of TCR transgenic mice. However the data so far available from mature DC stimulation experiments suggest that neither filarial MIF homologue activate DC, nor do they play an important role in initiating adaptive immune responses.

In addition to the observation that DC primed with helminth antigens drive Th-2 responses, there is evidence that parasite products can interfere with DC maturation and impair subsequent activation, a role that has been proposed as an important mechanism in immune down-modulation during filarial infection (Semnani et al., 2003; Sasisekhar et al., 2005). Moreover, parasite products may interfere with immune cells at a variety of differentiation and maturation stages, from immature monocytes in the blood, to fully differentiated DC and macrophages in the lymphatics (Semnani and Nutman, 2004).
Having previously shown that MIF homologues may play an important role in immune down-modulation by rendering macrophages suppressive, I therefore wanted to analyse the effect of MIF during myeloid differentiation and assess whether by altering DC differentiation Bm-MIF can inhibit immune responsiveness. BM cells were cultured under DC-differentiation conditions in the presence or absence of MIF recombinant protein. Both filarial MIF homologues delayed DC differentiation in a 9 day culture period, and by the end of the differentiation process Bm-MIF-2 had significantly reduced DC yields by maintaining the initial myeloid population. Moreover, CD11c+ DC generated in the presence of Bm-MIF-2 were MHC-II low suggesting they remained in an immature state. Furthermore, both Bm-MIF-1 and -2 differentiated DC showed impaired responsiveness to LPS as seen by diminished up-regulation of surface activation markers.
The observation of a CD11b+GR1+ population, initially suggested that Bm-MIF-2 might induce myeloid suppressor cells (MSC). MSC have been previously shown to play an important role in immune suppression during helminth infection (Brys et al., 2005). This population is characterised by expression of GR1 and CD11b along with F4/80 and CD115 (Huang et al., 2006), and their suppressor capacity is dependent on arginase-1 expression (Bronte et al., 2003). However, it was found that CD11b+GR1+ generated in the presence of Bm-MIF-2 were F4/80 low and CD115 negative, did not suppress T cell proliferation, and did not express Arginase-1. I therefore conclude that Bm-MIF-2 is impairing DC differentiation by increasing the survival of the initial myeloid undifferentiated population, rather than skewing cell differentiation towards a non-DC mature phenotype.
The enhancement of myeloid cell survival is evident in two settings. First, BM cell culture in the presence of MIF alone showed that all three homologues enhanced survival. Second, when culturing cells with M-CSF to promote macrophage differentiation, higher cell yields were obtained when cells were cultured with MIF homologues although the percentage of macrophages was lower. Moreover, these macrophages, as DC before, were hyporesponsive to LPS.
To further elucidate the role of MIF in myeloid differentiation, BM cells were cultured with different MIF homologues in the absence of any other stimuli. Cell cultured in media alone failed to expand, but the presence of MIF enhanced cell yields, although to a level 10 fold lower than with either M-CSF or GM-CSF.  In the absence of other differentiation stimulus, cells develop into macrophages by adherence to the tissue culture plate, in these conditions MIF enhanced macrophage percentages to a level equivalent to that achieved with M-CSF. 
Further studies are required to investigate the effect of MIF on macrophage development. It is possible that if MIF favours macrophage differentiation, cells cultured with M-CSF in the presence of MIF are being over-stimulated with a resultant decrease in percentages. However, MIF will enhance macrophage development in the absence of other differentiation factors. In the presence of GM-CSF, filarial MIF homologues (particularly Bm-MIF-2) impair DC differentiation but sustain undifferentiated myeloid cells; it is possible that these myeloid cells might differentiate into macrophages if the differentiation stimulus is changed. Culture of cells with GM-CSF and Bm-MIF-2 and exchanging the media to M-CSF at later times in the differentiation process might help answer this question. Furthermore, analysis of cell proliferation in the presence of MIF homologues will help distinguish whether MIF primarily influences cell survival or differentiation in vitro.

The MIF effect on DC differentiation is supported by the observation that BM-cell differentiation in the presence of live adult B. malayi worms also yielded lower numbers of CD11c+ DC but higher CD11b+GR1+ myeloid cells.  However further studies are needed to ascertain whether distinct components in Brugia ES contribute to this impairment in DC, or whether high levels of MIF alone are sufficient for this effect. 

The observations described above lead me to suggest that while Bm-MIF plays an important role in macrophage activation, and immune down-modulation by these activated macrophages, during the course of infection DC are not a major target for filarial MIF homologues. However, by delaying DC differentiation MIF homologues might be also diminishing immune responses, decreasing the number of activated DC. It is also possible that Bm-MIF might drive APC precursors towards increased macrophage numbers by altering myeloid differentiation at a critical stage. 

3	Host MIF does not play an important role during Brugia malayi infection.
Mammalian MIF has been shown to exert contrasting effects in different infection and disease processes (Lue et al., 2002). In general, low levels of MIF are beneficial for the host, and help prevent intracellular pathogen infection (Jüttner et al., 1998). However, in acute inflammatory situations an excess of MIF in the system is detrimental for the host, causing high inflammation and septic shock (Calandra et al., 2000). 
The absence of MIF during several parasitic infections has been shown to result in greater susceptibility as seen by an increase in parasite numbers. in both protozoa and helminth infection (Rodríguez-Sosa et al., 2003; Reyes et al., 2006). Studies with T. cruzi and L. major show that MIF-deficient mice are more susceptible to infection, attributed to the inability of MIF-deficient macrophages to kill intracellular parasites (Satoskar et al., 2001). MIF-deficient mice are also more susceptible to the helminth parasite T. crassiceps; deficient mice have higher parasite burdens accompanied by higher IL-13 and IFN-g production although no differences were observed in IL-4 production (Rodríguez-Sosa et al., 2003). Furthermore, anti-MIF antibody treatment in Schistosoma japonicum infected mice increased worm survival while decreasing IL-10 production (Stavitsky et al., 2003). The role of host MIF during filarial infection however has not previously been studied. 

To analyse the importance of host MIF in immune responses to B. malayi, we compared surgical implantation of adult worms in the peritoneal cavity of WT and MIF-deficient mice. Implantation is followed by an influx of eosinophils and macrophages to the peritoneal cavity. The macrophages are highly activated; they express Ym-1, Fizz-1 and Arginase-1, and have suppressor capacity. Furthermore, B. malayi implantation induces systemic Th-2 responses (Loke et al., 2002; MacDonald et al., 2003).
To assess the importance of MIF during infection, PEC differential cell count, macrophage activation state, and re-call responses were analysed. In the first set of experiments, the MIF deficient mice available were of a mixed genetic background and both C57BL/6 and 129 mice were used as WT controls. We observed lower eosinophilia in both C57BL/6 and MIF deficient mice compared to the 129 group suggesting that there are important strain difference effects. Furthermore, in these experiments re-call responses and alternative activation analyses were not consistent between experiments, as in one experiment type 2 responses in MIF-deficient mice were reduced while in a second experiment 129 and MIF–/– mice showed equivalent responses. 

By the end of the study, MIF-deficient mice on the BALB/c background became available, and so responses to B. malayi were studied in this strain. To our surprise both splenocyte Th-2 cytokine production, and macrophage alternative activation, were higher in MIF-deficient mice compared to the WT group. Although differences are significant, the infection of MIF deficient mice on the BALB/c background has only been performed once and, this experiment needs repeating for confirmation. However, higher IL-4, IL-5, IL-13 and IL-10 production by MIF-deficient mice, and stronger macrophage alternative activation seen by higher levels of Ym-1, Fizz-1, Arginase-1 and higher suppressor capacity, suggest that during infection host MIF might be controlling type 2 responses to Brugia malayi.

In the in vivo implant model is important to consider that B. malayi worms are secreting MIF throughout the infection period, and despite lack of host MIF, Brugia MIF will attract macrophages and induce their alternative activation. Antibody blockade of either parasite MIF, host MIF or all, will help discern the role of each MIF homologue during cell recruitment and alternative activation following B. malayi infection. The data from the BALB/c mice however, suggest that lack of mouse MIF increases type 2 responses to Brugia; it is possible that in vivo mouse-MIF interacts with Bm-MIF to control activation of the cells recruited.

4	Host and parasite MIF differences and similarities.
The initial hypothesis was that mouse-MIF would induce a pro-inflammatory phenotype, while Brugia homologues would favour an anti-inflammatory outcome more beneficial for the parasites. However I have found both similarities and differences in the effects exerted by both host and parasite MIF proteins. 
In the absence of other stimuli, mouse-MIF induced inflammatory cytokines from both DC and macrophages, whereas Brugia MIF homologues had little effect on DC and induced IL-10 from macrophages. These results supported the initial hypothesis, and raised the question that mouse-MIF and Brugia MIF might interact with APC in different ways.
CD74 has been proposed as the receptor for mouse-MIF (Leng et al., 2003), and initially I had hypothesised that the differences observed between mouse-MIF and Bm-MIF in macrophage activation in the absence of other stimuli might be due to differences in the interaction of both homologues with this receptor. However, studies with CD74-deficient macrophages did not show any differences between host and filarial MIF stimulation, nor were there any differences in cytokine production between WT and deficient macrophages. With these observations I conclude that in our system, CD74 is not important for MIF effect on macrophage activation as seen by cytokine production. 
Having demonstrated that filarial MIF have a strong effect on macrophages, but not so on DC; CD74 expression in these two cell populations is of interest. Macrophages showed little CD74 on the other hand DC expressed higher levels of this molecule. This observation supports the idea that in this system CD74 is not required for macrophage activation by MIF. Furthermore, the observation that only mammalian MIF induced DC activation suggests that CD74 is not the receptor for filarial MIF homologues. Despite high levels of the protein on the cells, Bm-MIF failed to activate DC.

A striking observation was that in the type 2 environment that typically develops during filarial infection, mimicked in vitro by the addition of IL-4, both mouse and Brugia MIF homologues enhanced macrophage alternative activation. This was an unexpected result, as mammalian MIF has been described as a strong inflammatory stimulus and its role has been well characterised in different type 1 situations (Calandra, 2003). However, recent data on the role of MIF in wound healing and angiogenesis (Hardman et al., 2005; Kim et al., 2007) suggest that mammalian MIF does indeed enhance alternative activation of macrophages, as these cells are involved in collagen deposition during these processes. 

Finally, it is important to notice the differences between the two filarial MIF homologues. At the protein level, Bm-MIF-1 and -2 share only 26 % amino acid identity; importantly, whereas both Bm-MIF-1 and -2 contain the tautomerase activity characteristic of MIF proteins, only Bm-MIF-1 conserves the amino acid motif needed for oxidorreductase activity (Zang et al., 2002). 
Whether for macrophage or DC activation, mouse MIF depends on its tautomerase activity, as mouse-MIFG induced lower activation as seen by lower surface markers, and decreased cytokine production. However, in neither Bm-MIF-1 or Bm-MIF-2 does the tautomerase play an important role in biological activity, as both Bm-MIF-1G and Bm-MIF-2G induced equivalent levels of cytokine production to the correspondent non-mutant protein.
More interesting are the differences observed between Bm-MIF-1 and -2 in macrophage alternative activation. During macrophage activation in a type 2 situation, both mouse-MIF and Bm-MIF-1 are dependent on the tautomerase activity being intact, as mouse-MIFG and Bm-MIF-1G mutants showed decreased effect enhancing IL-4-induced macrophage activation as seen by lower expression of alternative markers and suppression capacity, compared to the non-mutant proteins. However, both Bm-MIF-2 and Bm-MIF-2G induced the same levels of activation in the presence of IL-4. 
The final striking difference is the effect of the different MIF homologues on myeloid differentiation.  Culturing BM cells in the presence of either Bm-MIF-2 or Bm-MIF-2G greatly impaired DC development, whereas neither Bm-MIF-1, mouse-MIF or their corresponding G mutants had an effect on DC differentiation. 

The importance and inter-relationship of the tautomerase and oxidorreductase sites is an area requiring deeper analysis. For example, Bm-MIF-2 is the only one of the three homologues that does not have oxidorreductase activity. As abolishing tautomerase activity in Bm-MIF-2 does not alter its biological effect, but does in Bm-MIF-1 and mouse-MIF, the two sites might be interdependent. Generation of Bm-MIF-1 and mouse-MIF oxidorreductase-deficient mutants would help answer these questions. 

It is important to consider the role of tautomerase activity in filarial MIF homologues as previous studies have shown that tautomerase inhibitors can reduce inflammation and increase survival in septic shock (Al-Abed et al., 2005; Molnar and Garai, 2005). If Bm-MIF-1 tautomerase proves to be essential for its biological effect in vivo, the use of tautomerase inhibitors could help decrease the down-regulation induced by MIF during Brugia infection.
5	Final conclusions.
Based on my observations in vitro and in vivo, I propose the following scheme of how MIF homologues interact with APC during filarial infection, and the effect on the final immune response outcome (Fig. 7.1). During filarial infection Bm-MIF homologues induce macrophage recruitment to the site of infection (1) and once in contact with these cells, MIF induces cytokine production and IL-4Ra expression. The strong type 2 environment induced by Brugia (2) will in turn activate macrophages to an alternative phenotype, a process which is enhanced by the presence of both filarial and host MIF. Macrophages acquire a suppressive phenotype able to down-regulate T cell responses. 
As infection progresses and becomes chronic, both adult and microfilariae will encounter undifferentiated cells of the myeloid lineage (3). In this situation Bm-MIF-2 inhibits differentiation and maturation of myeloid cells into DC thus decreasing host capacity for initiation of immune responses.
































The following protocol was followed to generate monoclonal antibodies to Bm-MIF-1 and Bm-MIF-2. Two BALB/c mice were immunised with 50 µg of each alum precipitated recombinant protein and on days 28, 29 and 30 mice were boosted with 1 µg of recombinant protein intravenously. On day 31 mice were sacrificed and serum and spleens were collected.  Splenocyte suspensions were prepared from each mouse by mashing the cells through a cell strainer. Cells were then fused at a 1:1 ratio with the myeloma cell line SP2 using PEG as a fusing agent. Cells were plated drop-wise onto 96-well flat-bottom plates and incubated at 37ºC. Five plates per mouse were plated initially, and surplus splenocytes not used for cloning were frozen down and kept as back up. 








expand, and a third screen by ELISA was performed. Cells from positive wells in this third screen were recovered and expanded by culture in flasks. . 
2	Antibody reactivity.
ELISA tests of antibody binding were undertaken firstly to verify that monoclonal reactivity had remained intact through the subcloning process, and secondly to ascertain the degree of cross-reactivity with Heterologous MIF proteins. An irrelevant, non-MIF related B. malayi recombinant protein expressed using the same protocol, was also used. A total of 6 Bm-MIF-2 specific clones were found no to cross-react with any other MIF homologue (Fig. A1.3). However, the one clone originally raised against Bm-MIF-1 strongly cross-reacted with Bm-MIF-2, mouse-MIF and Litomosomoides sigmodontis (Ls-MIF), but not Pb-MIF or Bm-SPN-2. The non-reactivity with Pb-MIF and Bm-SPN-2 demonstrates that 2F11C9 is not an anti-His antibody, as all proteins used to coat the ELISA plate are recombinant His-tag protein expressed in E. coli. Furthermore, this clone recognises mouse-MIF but not Plasmodium MIF (Pb-MIF) suggesting that filarial MIF might share epitopes with mouse-MIF that are not present in the Plasmodium homologue.







One MAb specific for each Bm-MIF homologue, and the one that recognises both Bm-MIF and mouse-MIF were cultured in 500 ml of media and antibody was purified as described in materials and methods. 1.9A3E3D6 specifically recognises Bm-MIF-1, 5A7E5 specifically recognises Bm-MIF-2 and 2F11C9 recognises both Brugia MIF homologues and mouse-MIF.

To assess whether the antibodies generated have blocking capacity, BM-derived macrophages were treated with 10 µg of recombinant protein and increasing concentrations of each of the monoclonal antibody. Cytokine ELISA was chosen as the readout for MIF activity, Fig.A1.4.  None of the antibodies tested blocked cytokine induction by MIF at any of the concentrations tested.  






























A central problem dissecting the biological role of MIF is that the dynamics of expression are not well understood in vivo. It has already been established that mammalian MIF effects are strongly dose dependent (Calandra et al., 1995). Likewise the effect of parasite MIFs has been shown to be dose dependent by incubating cells with different concentrations of recombinant protein. More critically, such experiments mimic only punctual priming, whereas in vivo, ongoing MIF production may occur. To study situations where MIF proteins are continuously being expressed we need to use heterologous transfection systems for expression. To this end, expression of MIF proteins in mammalian cells was performed by transfection using a retroviral system.  Bm-MIF-1, -2 and mouse-MIF were cloned in the retroviral expression vector MIGR1 (Fig.A2.1) as described in Materials and Methods. MIGR1 is a bicistronic vector that encodes GFP directly after the gene of interest. 


1	Generation of retrovirus producing stable lines. 
MIGR1 is a replication deficient vector, and infective retrovirus can only be made by transfection into cell lines encoding the required retrovirus packaging genes. Fibroblast cell lines such as PT67 and GP+E.86 previously transfected with the retrovirus machinery are available for this purpose. 
In order to generate stable lines that will continuously produce retrovirus a double transfection ping-pong protocol was used. First PT-67 cells were transfected using Effectine (QIAgen). 48 h after transfection retrovirus containing supernatant was used to transduce GP+E.86 cells. GP+E.86 transduced cells were sorted by GFP positive selection and cells were expanded in culture. Figure A2.2 shows a schematic of the transfection protocol, and Figure A2.3 shows representative histograms of transfected PT-67 (top) and sorted GP+E.86 (bottom).
2	Transgene expression.
To confirm transduced GP+E.86 cells express the gene of interest, RT-PCR and western blot analysis was performed. Cells were collected in TRIzol for RNA extraction. RNA and first strand cDNA were generated as detailed in Materials and Methods. 1 µl of cDNA was used for PCR with Bm-MIF-1, Bm-MIF-2 and mouse-MIF specific primers; b-actin was amplified to control for reverse transcripition. 














3	Bone marrow cell transduction.
Bone marrow cells were cultured with rm-SCF and rm-IL-3 to induce proliferation. On day 3 cells were transduced with GP+E.86-derived retrovirus-containing supernatant as detailed in Materials and Methods. Transfection efficiency was monitored by GFP expression in flow cytometry at 48, 72 and 96 h.  As it can be seen in figure A2.5 transfection efficiency increases with time, but Bm-MIF-1 and -2 are less inefficient than empty MIGR1 and mouse-MIF transfected cells. 

In a second experiment transfected cells were sorted and transferred to GM-CSF containing media to assess whether MIF expression would inhibit DC differentiation. Table in figure A2.6a shows absolute numbers of cells before and after sorting. Cells were cultured in GM-CSF for 6 days, when their phenotype was analysed by flow cytometry, staining for CD11b, CD11c and F4/80.
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